Alzheimer&#39;s disease secretase

ABSTRACT

The present invention provides the enzyme and enzymatic procedures for cleaving the β secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays.

FIELD OF THE INVENTION

The present invention related to the field of Alzheimer's Disease, APP, amyloid beta peptide, and human aspartyl proteases as well as a method for the identification of agents that modulate the activity of these polypeptides.

BACKGROUND OF THE INVENTION

Alzheimer's disease (AD) causes progressive dementia with consequent formation of amyloid plaques, neurofibrillary tangles, gliosis and neuronal loss. The disease occurs in both genetic and sporadic forms whose clinical course and pathological features are quite similar. Three genes have been discovered to date which when mutated cause an autosomal dominant form of Alzheimer's disease. These encode the amyloid protein precursor (APP) and two related proteins, presenilin-1 (PS1) and presenilin-2 (PS2), which as their names suggest are both structurally and functionally related. Mutations in any of the three enhance proteolytic processing of APP via an intracellular pathway that produces amyloid beta peptide or the Aβ peptide (or sometimes here as Abeta), a 40-42 amino acid long peptide that is the primary component of amyloid plaque in AD. Dysregulation of intracellular pathways for proteolytic processing may be central to the pathophysiology of AD. In the case of plaque formation, mutations in APP, PS1 or PS2 consistently alter the proteolytic processing of APP so as to enhance formation of Aβ 1-42, a form of the Aβ peptide which seems to be particularly amyloidogenic, and thus very important in AD. Different forms of APP range in size from 695-770 amino acids, localize to the cell surface, and have a single C-terminal transmembrane domain. The Abeta peptide is derived from a region of APP adjacent to and containing a portion of the transmembrane domain Normally, processing of APP at the α-secretase site cleaves the midregion of the Aβ sequence adjacent to the membrane and releases the soluble, extracellular domain of APP from the cell surface. This α-secretase APP processing, creates soluble APP-α, and it is normal and not thought to contribute to AD.

Pathological processing of APP at the β- and γ-secretase sites produces a very different result than processing at the α site. Sequential processing at the β- and γ-secretase sites releases the Aβ peptide, a peptide possibly very important in AD pathogenesis. Processing at the β- and γ-secretase sites can occur in both the endoplasmic reticulum (in neurons) and in the endosomal/lysosomal pathway after reinternalization of cell surface APP (in all cells). Despite intense efforts, for 10 years or more, to identify the enzymes responsible for processing APP at the β and γ sites, to produce the Aβ peptide, those proteases remained unknown until this disclosure. Here, for the first time, we report the identification and characterization of the β secretase enzyme. We disclose some known and some novel human aspartic proteases that can act as β-secretase proteases and, for the first time, we explain the role these proteases have in AD. We describe regions in the proteases critical for their unique function and for the first time characterize their substrate. This is the first description of expressed isolated purified active protein of this type, assays that use the protein, in addition to the identification and creation of useful cell lines and inhibitors.

SUMMARY OF THE INVENTION

Here we disclose a number of variants of the asp2 gene and peptide.

Any isolated or purified nucleic acid polynucleotide that codes for a protease capable of cleaving the beta (β) secretase cleavage site of APP that contains two or more sets of special nucleic acids, where the special nucleic acids are separated by nucleic acids that code for about 100 to 300 amino acid positions, where the amino acids in those positions may be any amino acids, where the first set of special nucleic acids consists of the nucleic acids that code for the peptide DTG, where the first nucleic acid of the first special set of nucleic acids is, the first special nucleic acid, and where the second set of nucleic acids code for either the peptide DSG or DTG, where the last nucleic acid of the second set of nucleic acids is the last special nucleic acid, with the proviso that the nucleic acids disclosed in SEQ ID NO. 1 and SEQ. ID NO. 5 are not included. The nucleic acid polynucleotide of claim 1 where the two sets of nucleic acids are separated by nucleic acids that code for about 125 to 222 amino acid positions, which may be any amino acids. The nucleic acid polynucleotide of claim 2 that code for about 150 to 172 amino acid positions, which may be any amino acids. The nucleic acid polynucleotide of claim that code for about 172 amino acid positions, which may be any amino acids. The nucleic acid polynucleotide of claim 4 where the nucleotides are described in SEQ. ID. NO. 3 The nucleic acid polynucleotide of claim 2 where the two sets of nucleic acids are separated by nucleic acids that code for about 150 to 196 amino acid positions. The nucleic acid polynucleotide of claim 6 where the two sets of nucleotides are separated by nucleic acids that code for about 196 amino acids (positions). The nucleic acid polynucleotide of claim 7 where the two sets of nucleic acids are separated by the same nucleic acid sequences that separate the same set of special nucleic acids in SEQ. HD. NO. 5. The nucleic acid polynucleotide of claim 4 where the two sets of nucleic acids are separated by nucleic acids that code for about 150 to 190, amino acid (positions). The nucleic acid polynucleotide of claim 9 where the two sets of nucleotides are separated by nucleic acids that code for about 190 amino acids (positions). The nucleic acid polynucleotide of claim 10 where the two sets of nucleotides are separated by the same nucleic acid sequences that separate the same set of special nucleotides in SEQ. ID. NO. 1. Claims 1-11 where the first nucleic acid of the first special set of amino acids, that is, the first special nucleic acid, is operably linked to any codon where the nuclic acids of that codon codes for any peptide comprising from 1 to 10,000 amino acid (positions). The nucleic acid polynucleotide of claims 1-12 where the first special nucleic acid is operably linked to nucleic acid polymers that code for any peptide selected from the group consisting of: any any reporter proteins or proteins which facilitate purification. The nucleic acid polynucleotide of claims 1-13 where the first special nucleic acid is operably linked to nucleic acid polymers that code for any peptide selected from the group consisting of: immunoglobin-heavy chain, maltose binding protein, glutathion S transfection, Green Fluorescent protein, and ubiquitin. Claims 1-14 where the last nucleic acid of the second set of special amino acids, that is, the last special nucleic acid, is operably linked to nucleic acid polymers that code for any peptide comprising any amino acids from 1 to 10,000 amino acids. Claims 1-15 where the last special nucleic acid is operably linked to any codon linked to nucleic acid polymers that code for any peptide selected from the group consisting of: any reporter proteins or proteins which facilitate purification. The nucleic acid polynucleotide of claims 1-16 where the first special nucleic acid is operably linked to nucleic acid polymers that code for any peptide selected from the group consisting of immunoglobin-heavy chain, maltose binding protein, glutathion S transfection, Green Fluorescent protein, and ubiquitin.

Any isolated or purified nucleic acid polynucleotide that codes for a protease capable of cleaving the beta secretase cleavage site of APP that contains two or more sets of special nucleic acids, where the special nucleic acids are separated by nucleic acids that code for about 100 to 300 amino acid positions, where the amino acids in those positions may be any amino acids, where the first set of special nucleic acids consists of the nucleic acids that code for DTG, where the first nucleic acid of the first special set of nucleic acids is, the first special nucleic acid, and where the second set of nucleic acids code for either DSG or DTG, where the last nucleic acid of the second set of special nucleic acids is the last special nucleic acid, where the first special nucleic acid is operably linked to nucleic acids that code for any number of amino acids from zero to 81 amino acids and where each of those codons may code for any amino acid. The nucleic acid polynucleotide of claim 18, where the first special nucleic acid is operably linked to nucleic acids that code for any number of from 64 to 77 amino acids where each codon may code for any amino acid. The nucleic acid polynucleotide of claim 19, where the first special nucleic acid is operably linked to nucleic acids that code for 71 amino acids. The nucleic acid polynucleotide of claim 20, where the first special nucleic acid is operably linked to 71 amino acids and where the first of those 71 amino acids is the amino acid T. The nucleic acid polynucleotide of claim 21, where the polynucleotide comprises a sequence that is at least 95% identical to SEQ. ED. (Example 11). The nucleic acid polynucleotide of claim 22, where the complete polynucleotide comprises SEQ. ID. (Example 11). The nucleic acid polynucleotide of claim 18, where the first special nucleic acid is operably linked to nucleic acids that code for any number of from 40 to 54 amino acids where each codon may code for any amino acid. The nucleic acid polynucleotide of claim 24, where the first special nucleic acid is operably linked to nucleic acids that code for 47 amino acids. The nucleic acid polynucleotide of claim 20, where the first special nucleic acid is operably linked to 47 codons where the first those 47 amino acids is the amino acid E. The nucleic acid polynucleotide of claim 21, where the polynucleotide comprises a sequence that is at least 95% identical to SEQ. ID. (Example 10). The nucleic acid polynucleotide of claim 22, where the complete polynucleotide comprises SEQ. ID. (Example 10).

Any isolated or purified nucleic acid polynucleotide that codes for a protease capable of cleaving the beta (β) secretase cleavage site of APP that contains two or more sets of special nucleic acids, where the special nucleic acids are separated by nucleic acids that code for about 100 to 300 amino acid positions, where the amino acids in those positions may be any amino acids, where the first set of special nucleic acids consists of the nucleic acids that code for the peptide DTG, where the first nucleic acid of the first special set of amino acids is, the first special nucleic acid, and where the second set of special nucleic acids code for either the peptide DSG or DTG, where the last nucleic acid of the second set of special nucleic acids, the last special nucleic acid, is operably linked to nucleic acids that code for any number of codons from 50 to 170 codons. The nucleic acid polynucleotide of claim 29 where the last special nucleic acid is operably linked to nucleic acids comprising from 100 to 170 codons. The nucleic acid polynucleotide of claim 30 where the last special nucleic acid is operably linked to nucleic acids comprising from 142 to 163 codons. The nucleic acid polynucleotide of claim 31 where the last special nucleic acid is operably linked to nucleic acids comprising about 142 codons. The nucleic acid polynucleotide of claim 32 where the polynucleotide comprises a sequence that is al least 95% identical to SEQ. ID. (Example 9 or 10). The nucleic acid polynucleotide of claim 33, where the complete polynucleotide comprises SEQ. ID. (Example 9 or 10). The nucleic acid polynucleotide of claim 31 where the last special nucleic acid is operably linked to nucleic acids comprising about 163 codons. The nucleic acid polynucleotide of claim 35 where the polynucleotide comprises a sequence that is at least 95% identical to SEQ. ID. (Example 9 or 10). The nucleic acid polynucleotide of claim 36, where the to complete polynucleotide comprises SEQ. ID. (Example 9 or 10). The nucleic acid polynucleotide of claim 31 where the last special nucleic acid is operably linked to nucleic acids comprising about 170 codons. Claims 1-38 where the second set of special nucleid acids code for the peptide DSG, and optionally the first set of nucleic acid polynucleotide is operably linked to a peptide purification tag. Claims 1-39 where the nucleic acid polynucleotide is operably linked to a peptide purification tag which is six histidine. Claims 1-40 where the first set of special nucleic acids are on one polynucleotide and the second set of special nucleic acids are on a second polynucleotide, where both first and second polynucleotides have at lease 50 codons. Claims 1-40 where the first set of special nucleic acids are on one polynucleotide and the second set of special nucleic acids are on a second polynucleotide, where both first and second polynucleotides have at lease 50 codons where both said polynucleotides are in the same solution. A vector which contains a polynucleotide described in claims 142. A cell or cell line which contains a polynucleotide described in claims 142.

Any isolated or purified peptide or protein comprising an amino acid polymer that is a protease capable of cleaving the beta (β) secretase cleavage site of APP that contains two or more sets of special amino acids, where the special amino acids are separated by about 100 to 300 amino acid positions, where each amino acid position can be any amino acid, where the first set of special amino acids consists of the peptide DTG, where the first amino acid of the first special set of amino acids is, the first special amino acid, where the second set of amino acids is selected from the peptide comprising either DSG or DTG, where the last amino acid of the second set of special amino acids is the last special amino acid, with the proviso that the proteases disclosed in SEQ ID NO. 2 and SEQ. ID NO. 6 are not included. The amino acid polypeptide of claim 45 where the two sets of amino acids are separated by about 125 to 222 amino acid positions where in each position it may be any amino acid. The amino acid polypeptide of claim 46 where the two sets of amino acids are separated by about 150 to 172 amino acids. The amino acid polypeptide of claim 47 where the two sets of amino acids are separated by about 172 amino acids. The amino acid polypeptide of claim 48 where the protease is described in SEQ. ID. NO.4 The amino acid polypeptide of claim 46 where the two sets, of amino acids are separated by about 150 to 196 amino acids. The amino acid polypeptide of claim 50 where the two sets of amino acids are separated by about 196 amino acids. The amino acid polypeptide of claim 51 where the two sets of amino acids are separated by the same amino acid sequences that separate the same set of special amino acids in SEQ. ID. NO. 6. The amino acid polypeptide of claim 46 where the two sets of amino acids are separated by about 150 to 190, amino acids. The amino acid polypeptide of claim 53 where the two sets of nucleotides are separated by about 190 amino acids. The amino acid polypeptide of claim 54 where the two sets of nucleotides are separated by the same amino acid sequences that separate the same set of special amino acids in SEQ. ID. NO. 2. Claims 45-55 where the first amino acid of the first special set of amino acids, that is, the first special amino acid, is operably linked to any peptide comprising from 1 to 10,000 amino acids. The amino acid polypeptide of claims 45-56 where the first special amino acid is operably linked to any peptide selected from the group consisting of: any any reporter, proteins or proteins which facilitate purification. The amino acid polypeptide of claims 45-57 where the first special amino acid is operably linked to any peptide selected from the group consisting of: immunoglobin-heavy chain, maltose binding protein, glutathion S transfection, Green Fluorescent protein, and ubiquitin. Claims 45-58, where the last amino acid of the second set of special amino acids, that is, the last special amino acid, is operably linked to any peptide comprising any amino acids from 1 to 10,000 amino acids. Claims 45-59 where the last special amino acid is operably linked any peptide selected from the group consisting of any reporter proteins or proteins which facilitate purification. The amino acid polypeptide of claims 45-60 where the first special amino acid is operably linked to any peptide selected from the group consisting of: immunoglobin-heavy chain, maltose binding protein, glutathion S transfection, Green Fluorescent protein, and ubiquitin.

Any isolated or purified peptide or protein comprising an amino acid polypeptide that codes for a protease capable of cleaving the beta secretase cleavage site of APP that contains two or more sets of special amino acids, where the special amino acids are separated by about 100 to 300 amino acid positions, where each amino acid in each position can be any amino acid, where the first set of special amino acids consists of the amino acids DTG, where the first amino acid of the first special set of amino acids is, the first special amino acid, D, and where the second set of amino acids is either DSG or DTG, where the last amino acid of the second set of special amino acids is the last special amino acid, G, where the first special amino acid is operably linked to amino acids that code for any number of amino acids from zero to 81 amino acid positions where in each position it may be any amino acid. The amino acid polypeptide of claim 62, where the first special amino acid is operably linked to a peptide from about 64 to 77 amino acids positions where each amino acid position may be any amino acid. The amino acid polypeptide of claim 63, where the first special amino acid is operably linked to a peptide of 71 amino acids. The amino acid polypeptide of claim 64, where the first special amino acid is operably linked to 71 amino acids and the first of those 71 amino acids is the amino acid T. The amino acid polypeptide of claim 65, where the polypeptide comprises a sequence that is at least 95% identical to SEQ. ID. (Example 11). The amino acid polypeptide of claim 66, where the complete polypeptide comprises SEQ. ID. (Example 11). The amino acid polypeptide of claim 62, where the first special amino acid is operably linked to any number of from 40 to 54 amino acids (positions) where each amino acid position may be any amino acid. The amino acid polypeptide of claim 68, where the first special amino acid is operably linked to amino acids that code for a peptide of 47 amino acids. The amino acid polypeptide of claim 69, where the first special amino acid is operably linked to a 47 amino acid peptide where the first those 47 amino acids is the amino acid E. The amino acid polypeptide of claim 70, where the polypeptide comprises a sequence that is at least 95% identical to SEQ. ID. (Example 10). The amino acid polypeptide where the polypeptide comprises Example 10). Any isolated or purified amino acid polypeptide that is a protease capable of cleaving the beta (β) secretase cleavage site of APP that contains two or more sets of special amino acids, where the special amino acids are separated by about 100 to 300 amino acid positions, where each amino acid in each position can be any amino acid, where the first set of special amino acids consists of the amino acids that code for DTG, where the first amino acid of the first special set of amino acids is, the first special amino acid, D, and where the second set of amino acids are either DSG or DTG, where the last amino acid of the second set of special amino acids is the last special amino acid, G, which is operably linked to any number of amino acids from 50 to 170 amino acids, which may be any amino acids. The amino acid polypeptide of claim 73 where the last special amino acid is operably linked to a peptide of about 100 to 170 amino acids. The amino acid polypeptide of claim 74 where the last special amino acid is operably linked to to a peptide of about 142 to 163 amino acids. The amino acid polypeptide of claim 75 where the last special amino acid is operably linked to to a peptide of about about 142 amino acids. The amino acid polypeptide of claim 76 where the polypeptide comprises a sequence that is at least 95% identical to SEQ. ID. (Example 9 or 10). The amino acid polypeptide of claim 75 where the last special amino acid is operably linked to a peptide of about 163 amino acids. The amino acid polypeptide of claim 79 where the polypeptide comprises a sequence that is at least 95% identical to SEQ. I). (Example 9 or 10). The amino acid polypeptide of claim 79, where the complete polypeptide comprises SEQ. ID. (Example 9 or 10). The amino acid polypeptide of claim 74 where the last special amino acid is operably linked to to a peptide of about 170 amino acids. Claim 46-81 where the second set of special amino acids is comprised of the peptide with the amino acid sequence DSG. Claims 45-82 where the amino acid polypeptide is operably linked to a peptide purification tag. Claims 45-83 where the amino acid polypeptide is operably linked to a peptide purification tag which is six histidine. Claims 45-84 where the first set of special amino acids are on one polypeptide and the second set of special amino acids are on a second polypeptide, where both first and second polypeptide have at lease 50 amino acids, which may be any amino acids. Claims 45-84 where the first set of special amino acids are on one polypeptide and the second set of special amino acids are on a second polypeptide, where both first and second polypeptides have at lease 50 amino acids where both said polypeptides are in the same vessel. A vector which contains a polypeptide described in claims 45-86. A cell or cell line which contains a polynucleotide described in claims 45-87. The process of making any of the polynucleotides, vectors, or cells of claims 1-44. The process of making any of the polypeptides, vectors or cells of claim 45-88. Any of the polynucleotides, polypeptides, vectors, cells or cell lines described in claims 1-88 made from the processes described in claims 89 and 90.

Any isolated or purified peptide or protein comprising an amino acid polypeptide that codes for a protease capable of cleaving the beta secretase cleavage site of APP that contains two or more sets of special amino acids, where the special amino acids are separated by about 100 to 300 amino acid positions, where each amino acid in each position can be any amino acid, where the first set of special amino acids consists of the amino acids DTG, where the first amino acid of the first special set of amino acids is, the first special amino acid, D, and where the second set of amino acids is either DSG or DTG, where the last amino acid of the second set of special amino acids is the last special amino acid, G, where the first special amino acid is operably linked to amino acids that code for any number of amino acids from zero to 81 amino acid positions where in each position it may be any amino acid.

The amino acid polypeptide of claim 62, where the first special amino acid is operably linked to a peptide from about 30 to 77 amino acids positions where each amino acid position may be any amino acid. The amino acid polypeptide of claim 63, where the first special amino acid is operably linked to a peptide of 35, 47, 71, or 77 amino acids.

The amino acid polypeptide of claim 63, where the first special amino acid is operably linked to the same corresponding peptides from SEQ. ID. NO. 3 that are 35, 47, 71, or 77 peptides in length, beginning counting with the amino acids on the first special sequence. DTG, towards the N-terminal of SEQ. ID. NO. 3.

The amino acid polypeptide of claim 65, where the polypeptide comprises a sequence that is at least 95% identical to the same corresponding amino acids in SEQ. ID. NO. 4, that is, identical to that portion of the sequences in SEQ. ID. NO. 4, including all the sequences from both the first and or the second special nucleic acids, toward the N-terminal, through and including 71, 47, 35 amino acids before the first special amino acids. (Examples 10 and 11).

The amino acid polypeptide of claim 65, where the complete polypeptide comprises the peptide of 71 amino acids, where the first of the amino acid is T and the second is Q. The nucleic acid polynucleotide of claim 21, where the polynucleotide comprises a sequence that is at least 95% identical to the same corresponding amino acids in SEQ. ID. NO.3, that is, identical to the sequences in SEQ. ID. NO. 3 including the sequences from both the first and or the second special nucleic acids, toward the N-Terminal, through and including 71 amino acids, see Example 10, beginning from the DTG site and including the nucleotides from that code for 71 amino acids).

The nucleic acid polynucleotide of claim 22, where the complete polynucleotide comprises identical to the same corresponding amino acids in SEQ. ID. NO. 3, that is, identical to the sequences in SEQ. ID. NO. 3 including the sequences from both the first and or the second special nucleic acids, toward the N-Terminal, through and including 71 amino acids, see Example 10, beginning from the DTG site and including the nucleotides from that code for 71 amino acids).

The nucleic acid polynucleotide of claim 18, where the first special nucleic acid is operably linked to nucleic acids that code for any number of from about 30 to 54 amino acids where each codon may code for any amino acid.

The nucleic acid polynucleotide of claim 20, where the first special nucleic acid is operably linked to 47 codons where the first those 35 or 47 amino acids is the amino acid E or G.

The nucleic acid polynucleotide of claim 21, where the polynucleotide comprises a sequence that is at least 95% identical to the same corresponding amino acids in SEQ. ID. NO. 3, that is, identical to that portion of the sequences in SEQ. ID. NO. 3 including the sequences from both the first and or the second special nucleic acids, toward the N-Terminal, through and including 35 or 47 amino acids, see Example 11 for the 47 example, beginning from the DTG site and including the nucleotides from that code for the previous 35 or 47 amino acids before the DTG site). The nucleic acid polynucleotide of claim 22, where the polynucleotide comprises identical to the same corresponding amino acids in SEQ. ID. NO. 3, that is, identical to the sequences in SEQ. ID. NO. 3 including the sequences from both the first and or the second special nucleic acids, toward the N-Terminal, through and including 35 or 47 amino acids, see Example 11 for the 47 example, beginning from the DTG site and including the nucleotides from that code for the previous 35 or 47 amino acids before the DTG site).

An isolated nucleic acid molecule comprising a polynucleotide, said polynucleotide encoding a Hu-Asp polypeptide and having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:

-   -   (a) a nucleotide sequence encoding a Hu-Asp polypeptide selected         from the group consisting of Hu-Asp1, Hu-Asp2(a), and         Hu-Asp2(b), wherein said Hu-Asp1. Hu-Asp2(a) and Hu-Asp2(b)         polypeptides have the complete amino acid sequence of SEQ ID         No. 2. SEQ ID No. 4, and SEQ ID No. 6, respectively; and     -   (b) a nucleotide sequence complementary to the nucleotide         sequence of (a).

The nucleic acid molecule of claim 92, wherein said Hu-Asp polypeptide is Hu-Asp1, and said polynucleotide molecule of 1(a) comprises the nucleotide sequence of SEQ ID No. 1. The nucleic acid molecule of claim 92, wherein said Hu-Asp polypeptide is Hu-Asp2(a), and said polynucleotide molecule of 1(a) comprises the nucleotide sequence of SEQ ID No. 4. The nucleic acid-molecule of claim 92, wherein said Hu-Asp polypeptide is Hu-Asp2(b), and said polynucleotide molecule of 1(a) comprises the nucleotide sequence of SEQ ID No. 5. An isolated nucleic acid molecule comprising polynucleotide which hybridizes under stringent conditions to a polynucleotide having the nucleotide sequence in (a) or (b) of claim 92. A vector comprising the nucleic acid molecule of claim 96. The vector of claim 97, wherein said nucleic acid molecule is operably linked to a promoter for the expression of a Hu-Asp polypeptide. The vector of claim 98, wherein said Hu-Asp polypeptide is Hu-Asp1. The vector of claim 98, wherein said Hu-Asp polypeptide is Hu-Asp2(a). The vector of claim 98, wherein said Hu-Asp polypeptide is Hu-Asp2(b). A host cell comprising the vector of claim 98. A method of obtaining a Hu-Asp polypeptide comprising culturing the host cell of claim 102 and isolating said Hu-Asp polypeptide. An isolated Hu-Asp1 polypeptide comprising an amino acid sequence at least 95% identical to a sequence comprising the amino acid sequence of SEQ ID No. 2. An isolated Hu-Asp2(a) polypeptide comprising an amino acid sequence at least 95% identical to a sequence comprising the amino acid sequence of SEQ ID No. 4. An isolated Hu-Asp2(a) polypeptide comprising an amino acid sequence at least 95% identical to a sequence comprising the amino acid sequence of SEQ ID No. 8. An isolated antibody that binds specifically to the Hu-Asp polypeptide of any of claims 104-107.

Here we disclose numerous methods to assay the enzyme.

A method to identify a cell that can be used to screen for inhibitors of β secretase activity comprising:

-   -   (a) identifying a cell that expresses a protease capable of         cleaving APP at the β secretase site, comprising:         -   i) collect the cells or the supernantent from the cells to             be identified         -   ii) measure the production of a critical peptide, where the             critical peptide is selected from the group consisting of             either the APP C-terminal peptide or soluble APP,         -   iii) select the cells which produce the critical peptide.

The method of claim 108 where the cells are collected and the critical peptide is the APP C-terminal peptide created as a result of the β secretase cleavage. The method of claim 108 where the supernantent is collected and the critical peptide is soluble APP where the soluble APP has a C-terminal created by β secretase cleavage. The method of claim 108 where the cells contain any of the nucleic acids or polypeptides of claims 1-86 and where the cells are shown to cleave the β secretase site of any peptide having the following peptide structure P2, P1, P1′, P2′, where P2 is K or N, where P1 is M or L, where P1′ is D, where P2 is A. The method of claim 111 where P2 is K and P1 is M. The method of claim 112 where P2 is N and P1 is L

Any bacterial cell comprising any nucleic acids or peptides in claims 1-86 and 92-107. A bacterial cell of claim 114 where the bacteria is E coli. Any eukaryotic cell comprising any nucleic acids or polypeptides in claims 1-86 and 92-107.

Any insect cell comprising any of the nucleic acids or polypeptides in claims 1-86 and 92-107. A insect cell of claim 117 where the insect is sf9, or High 5. A insect cell of claim 100 where the insect cell is High 5. A mammalian cell comprising any of the nucleic acids or polypeptides in claims 1-86 and 92-107. A mammalian cell of claim 120 where the mammalian cell is selected from the group consisting of, human, rodent, lagomorph, and primate. A mammalian cell of claim 121 where the mammalian cell is selected from the group consisting of human cell. A mammalian cell of claim 122 where the human cell is selected from the group comprising HEK293, and IMR-32. A mammalian cell of claim 121 where the cell is a primate cell. A primate cell of claim 124 where the primate cell is a COS-7 cell. A mammalian cell of claim 121 where cell is selected from a rodent cells. A rodent cell of claim 126 selected from, CHO-K1, Neuro-2A, 3T3 cells. A yeast cell of claim 115. An avian cell of claim 115.

Any isoform of APP where the last two carboxy terminus amino acids of that isoform are both lysine residues. In written descrip. Define isoform is any APP polypeptide, including APP variants (including mutations), and APP fragments that exists in humans such as those described in U.S. Pat. No. 5,766,846, col 7, lines 45-67, incorporated into this document by reference. The isoform of APP from claim 114, comprising the isoform known as APP695 modified so that its last two having two lysine residues as its last two carboxy terminus amino acids. The isoform of claim 130 comprising SEQ. ID. 16. The isoform variant of claim 130 comprising SEQ. ID. NO. 18, and 20. Any eukaryotic cell line, comprising nucleic acids or polypeptides of claim 130-132. Any cell line of claim 133 that is a mammalian cell line (HEK293, Neuro2a, best-plus others. A method for identifying inhibitors of an enzyme that cleaves the beta secretase cleavabe site of APP comprising:

-   -   a) culturing cells in a culture medium under conditions in which         the enzyme causes processing of APP and release of amyloid         beta-peptide into the medium and causes the accumulation of         CTF99 fragments of APP in cell lysates,     -   b) exposing the cultured cells to a test compound; and         specifically determining whether the test compound inhibits the         function of the enzyme by measuring the amount of amyloid         beta-peptide released into the medium and or the amount of CTF99         fragments of APP in cell lysates;     -   c) identifying test compounds diminishing the amount of soluble         amyloid beta peptide present in the culture medium and         diminution of CTF99 fragments of APP in cell lysates as Asp2         inhibitors.

The method of claim 135 wherein the cultured cells are a human, rodent or insect cell line. The method of claim 136 wherein the human or rodent cell line exhibits β secretase activity in which processing of APP occurs with release of amyloid beta-peptide into the culture medium and accumulation of CTF99 in cell lysates. A method as in claim 137 wherein the human or rodent cell line treated with the antisense oligomers directed against the enzyme that exhibits β secretase activity, reduces release of soluble amyloid beta-peptide into the culture medium and accumulation of CTF99 in cell lysates. A method for the identification of an agent that decreases the activity of a Hu-Asp polypeptide selected from the group consisting of Hu-Asp1, Hu-Asp2(a), and Hu-Asp2(b), the method comprising:

-   -   a) determining the activity of said Hu-Asp polypeptide in the         presence of a test agent and in the absence of a test agent; and     -   b) comparing the activity of said Hu-Asp polypeptide determined         in the presence of said test agent to the activity of said         Hu-Asp polypeptide determined in the absence of said test agent;         whereby a lower level of activity in the presence of said test         agent than in the absence of said test agent indicates that said         test agent has decreased the activity of said Hu-Asp         polypeptide. The nucleic acids, peptides, proteins, vectors,         cells and cell lines, and assays described herein.

The present invention provides isolated nucleic acid molecules comprising a polynucleotide that codes for a polypeptide selected from the group consisting of human aspartyl proteases. In particular, human aspartyl protease 1 (Hu-Asp1) and two alternative splice variants of human aspartyl protease 2 (Hu-Asp2), designated herein as Hu-Asp2(a) and Hu-Asp2(b). As used herein, all references to “Hu-Asp” should be understood to refer to all of Hu-Asp1, Hu-Asp2(a), and Hu-Asp2(b). In addition, as used herein, all references to “Hu-Asp2” should be understood to refer to both Hu-Asp2(a) and Hu-Asp2(b). Hu-Asp1 is expressed most abundantly in pancreas and prostate tissues, while Hu-Asp2(a) and Hu-Asp2(b) are expressed most abundantly in pancreas and brain tissues. The invention also provides isolated Hu-Asp1, Hu-Asp2(a), and Hu-Asp2(b) polypeptides, as well as fragments thereof which exhibit aspartyl protease activity.

In a preferred embodiment, the nucleic acid molecules comprise a polynucleotide having a nucleotide sequence selected from the group consisting of residues 1-1554 of SEQ ID NO: 1, encoding Hu-Asp1, residues 1-1503 of SEQ ID NO:3, encoding Hu-Asp2(a), and residues 1-1428 of SEQ ID NO:5, encoding Hu-Asp2(b). In another aspect, the invention provides an isolated nucleic acid molecule comprising a polynucleotide which hybridizes under stringent conditions to a polynucleotide encoding Hu-Asp1, Hu-Asp2(a), Hu-Asp-2(b), or fragments thereof. European patent application EP 0 848 062 discloses a polypeptide referred to as “Asp 1,” that bears substantial homology to Hu-Asp1, while international application WO 98/22597 discloses a polypeptide referred to as “Asp 2,” that bears substantial homology to Hu-Asp2(a).

The present invention also provides vectors, comprising the isolated nucleic acid molecules of the invention, host cells into which such vectors have been introduced, and recombinant methods of obtaining a Hu-Asp1, Hu-Asp2(a), or Hu-Asp2(b) polypeptide comprising culturing the above-described host cell and isolating the relevant polypeptide.

In another aspect, the invention provides isolated Hu-Asp1, Hu-Asp2(a), and Hu-Asp2(b) polypeptides, as well as fragments thereof. In a preferred embodiment, the Hu-Asp1, Hu-Asp2(a), and Hu-Asp2(b) polypeptides have the amino acid sequence given in SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:6, respectively. The present invention also describes active forms of Hu-Asp2, methods for preparing such active forms, methods for preparing soluble forms, methods for measuring Hu-Asp2 activity, and substrates for Hu-Asp2 cleavage. The invention also describes antisense oligomers targeting the Hu-Asp1, Hu-Asp2(a) and Hu-Asp2(b) mRNA transcripts and the use of such antisense reagents to decrease such mRNA and consequently the production of the corresponding polypeptide. Isolated antibodies, both polyclonal and monoclonal, that binds specifically to any of the Hu-Asp1, Hu-Asp2(a), and Hu-Asp2(b) polypeptides of the invention are also provided.

The invention also provides a method for the identification of an agent that modulates the activity of any of Hu-Asp-1, Hu-Asp2(a), and Hu-Asp2(b). The inventions describes methods to test such agents in cell-free assays to which Hu-Asp2 polypeptide is added, as well as methods to test such agents in human or other mammalian cells in which Hu-Asp2 is present

BRIEF DESCRIPTION OF THE SEQUENCE LISTINGS

-   Sequence ID No.1-Human Asp-I, nucleotide sequence -   Sequence ID No.2-Human Asp-1, predicted amino acid sequence -   Sequence ID No.3-Human Asp-2(a), nucleotide sequence -   Sequence ID No.4-Human Asp-2(a), predicted amino acid sequence -   Sequence ID No.5-Human Asp-2(b), nucleotide sequence -   Sequence ID No.6-Human Asp-2(b), predicted amino acid sequence -   Sequence ID No.7-Murine Asp-2(a), nucleotide sequence -   Sequence ID No.8-Murine Asp-2(a), predicted amino acid sequence -   Sequence ID No.9-Human APP695, nucleotide sequence -   Sequence ID No.10-Human APP695, predicted amino acid sequence -   Sequence ID No.11-Human APP695-Sw, nucleotide sequence -   Sequence ID No.12-Human APP695-Sw, predicted amino acid sequence -   Sequence ID No.13-Human APP695-VF, nucleotide sequence -   Sequence ID No.14-Human APP695-VF, predicted amino acid sequence -   Sequence ID No.15-Human APP695-KK, nucleotide sequence -   Sequence ID No.16-Human APP695-KK, predicted amino acid sequence -   Sequence ID No.17-Human APP695-Sw-MK, nucleotide sequence -   Sequence ID No.18-Human APP695-Sw-KK, predicted amino acid sequence -   Sequence ID No.19-Human APP695-VF-KK, nucleotide sequence -   Sequence ID No.20-Human APP695-VF-KK, predicted amino acid sequence -   Sequence ID No.21-T7-Human-pro-Asp-2(a)ΔTM, nucleotide sequence -   Sequence ID No.22-T7-Human-pro-Asp-2(a)ΔTM, amino acid sequence -   Sequence ID No.23-T7-Caspase-Human-pro-Asp-2(a)ΔTM, nucleotide     sequence -   Sequence ID No.24-T7-Caspase-Human-pro-Asp-2(a)ΔTM, amino acid     sequence -   Sequence ID No.25-Human-pro-Asp-2(a)ΔTM (low GC), nucleotide     sequence -   Sequence ID No.26-Human-pr-Asp-2(a)ΔTM, (low GC), amino acid     sequence -   Sequence ID No.27-T7-Caspase-Caspase 8     cleavage-Human-pro-Asp-2(a)ΔTM, nucleotide sequence -   Sequence ID No.28-T7-Caspase-Caspase 8     cleavage-Human-pro-Asp-2(a)ΔTM, amino acid sequence -   Sequence ID No.29-Human Asp-2(a)ΔTM, nucleotide sequence -   Sequence ID No.30-Human Asp-2(a)ΔTM, amino acid sequence -   Sequence ID No.31-Human Asp-2(a)ΔTM(His)₆, nucleotide sequence -   Sequence ID No.32-Human Asp2(a)ΔTM(His)₆, amino acid sequence -   Sequence ID No.s 33-46 are described below in the Detailed     Description of the Invention.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1: FIG. 1 shows the nucleotide (SEQ ID NO:1) and predicted amino acid sequence (SEQ D) NO:2) of human Asp1.

FIG. 2: FIG. 2 shows the nucleotide (SEQ ID NO:3) and predicted amino acid sequence (SEQ ID NO:4) of human Asp2(a).

FIG. 3: FIG. 3 shows the nucleotide (SEQ ID NO:5) and predicted amino acid sequence (SEQ ID NO:6) of human Asp2(b). The predicted transmembrane domain of Hu-Asp2(b) is enclosed in brats.

FIG. 4: FIG. 4 shows the nucleotide (SEQ ID No. 7) and predicted amino acid sequence (SEQ ID No. 8) of murine Asp2(a)

FIG. 5: FIG. 5 shows the BestFit alignment of the predicted amino acid sequences of Hu-Asp2(a) and murine Asp2(a)

FIG. 6: FIG. 6 shows the nucleotide(SEQ ID No. 21) and predicted amino acid sequence (SEQ ID No. 22) of T7-Human-pro-Asp-2(a)ΔTM.

FIG. 7: FIG. 7 shows the nucleotide (SEQ ID No. 23) and predicted amino acid sequence (SEQ ID No. 24) of T7-caspase-Human-pro-Asp-2(a)ΔTM

FIG. 8: FIG. 8 shows the nucleotide (SEQ ID No. 25) and predicted amino acid sequence (SEQ ID No. 26) of Human-pro-Asp-2(a)ΔTM (low GC)

FIG. 9: Western blot showing reduction of CTF99 production by HEK125.3 cells transfected with antisense oligomers targeting the Hu-Asp2 Mrna

FIG. 10: Western blot showing increase in CTF99 production in mouse Neuro-2a cells cotransfected with APP-KK with and without Hu-Asp2 only in those cells cotransfected with Hu-Asp2. A further increase in CTF99 production is seen in cells cotransfected with APP-Sw-KK with and without Hu-Asp2 only in those cells cotransfected with Hu-Asp2

FIG. 11: FIG. 11 shows the predicted amino acid sequence (SEQ ED No. 30) of Human-Asp2(a)ΔTM

FIG. 12: FIG. 11 shows the predicted amino acid sequence (SEQ D No. 30) of Human-Asp2(a)ΔTM(His)₆

DETAILED DESCRIPTION OF THE INVENTION

A few definitions used in this invention follow, most definitions to be used arm those that would be used by one ordinarily skilled in the art

When the β amyloid peptide any peptide resulting from beta secretase cleavage of APP. This includes, peptides of 39, 40, 41, 42 and 43 amino acids, extending from the β-secretase cleavage site to 39, 40, 41, 42 and 43 amino acids. β amyloid peptide also means sequences 1-6, SEQ. ID. NO. 1-6 of U.S. Pat. No. 5,750,349, issued 12 May 1998 (incorporated into this document by reference). A β-secretase cleavage fragment disclosed here is called CIF-99, which extends from β-secretase cleavage site to the carboxy terminus of APP. When an isoform of APP is discussed then what is meant is any APP polypeptide, including APP variants (including mutations), and APP fragments that exists in humans such as those described in U.S. Pat. No. 5,766,846, col 7, lines 45-67, incorporated into this document by reference and see below.

The term “β-amyloid precursor protein” (APP) as used herein is defined as a polypeptide that is encoded by a gene of the same name localized in humans on the long arm of chromosome 21 and that includes “βAP—here “β-amyloid protein” see above, within its carboxyl third. APP is a glycosylated, single-membrane spanning protein expressed in a wide variety of cells in many mammalian tissues. Examples of specific isotypes of APP which are currently known to exist in humans are the 695-amino acid polypeptide described by Kang et. al. (1987) Nature 325:733-736 which is designated as the normal” APP; the 751-amino acid polypeptide described by Ponte et al. (1988) Nature 331:525-527 (1988) and Tanzi et al. (1988) Nature 331:528-530; and the 770-amino acid polypeptide described by Kitaguchi et al. (1988) Nature 331:530-532. Examples of specific variants of APP include point mutation which can differ in both position and phenotype (for review of known variant mutation see Hardy (1992) Nature Genet. 1:233-234). All references cited here incorporated by reference. The term “APP fragments” as used herein refers to fragments of APP other than those which consist solely of βAP or βAP fragments. That is, APP fragments will include amino acid sequences of APP in addition to those which form intact 3AP or a fragment of βAP.

When the term “any amino acid” is used, the amino acids referred to are to be selected from the following, three letter and single letter abbreviations—which may also be used, are provided as follows:

Alanine, Ala, A; Arginine, Arg, R; Asparagine, Asn, N; Aspartic acid, Asp, D; Cystein, Cys, C; Glutamine, Gln, Q; lu; E-Glutamic Acid, Glu, E; Glycine, Gly, G; Histidine, His, H; Isoleucine, Ile, I; Leucine, Leu, L; Lysine, Lys, K; Methioaine, Met, M; Phenylalanine, Phe, F; Proline, Pro, P; Serine, Ser, S; Threonine, Thr, T; Tryptophan. Trp, W; Tyrosine, Tyr, Y; Valine, Val, V; Aspartic acid or Aspanrgine, Asx, B; Glutamic acid or Glutamine, Glx, Z; Any amino acid, Xaa, X.

The present invention describes a method to scan gene databases for the simple active site motif characteristic of aspartyl proteases. Eukaryotic aspartyl proteases such as pepsin and renin possess a two-domain structure which folds to bring two aspartyl residues into proximity within the active site. These are embedded in the short tripeptide motif DTG, or more rarely, DSG. Most aspartyl proteases occur as proenzyme whose N-terminus must be cleaved for activation. The DTG or DSG active site motif appears at about residue 65-70 in the proenzyme (prorenin, pepsinogen), but at about residue 25-30 in the active enzyme after cleavage of the N-terminal prodomain. The limited length of the active site motif makes it difficult to search collections of short, expressed sequence tags (EST) for novel aspartyl proteases. EST sequences typically average 250 nucleotides or less, and so would encode 80-90 amino acid residues or less. That would be too short a sequence to span the two active site motifs. The preferred method is to scan databases of hypothetical or assembled protein coding sequences. The present invention describes a computer method to identify candidate aspartyl proteases in protein sequence databases. The method was used to identify seven candidate aspartyl protease sequences in the Caenorhabditis elegans genome. These sequences were then used to identify by homology search Hu-Asp1 and two alternative splice variants of Hu-Asp2, designated herein as Hu-Asp2(a) and Hu-Asp2(b).

In a major aspect of the invention disclosed here we provide new information about APP processing. Pathogeneic processing of the amyloid precursor protein (APP) via the Aβ pathway requires the sequential action of two proteases referred to as β-secretase and γ-secretase. Cleavage of APP by the β-secretase and γ-secretase generates the N-terminus and C-terminus of the Aβ peptide, respectively. Because over production of the Aβ peptide, particularly the Aβ₁₋₄₂, has been implicated in the initiation of Alzheimer's disease, inhibitors of either the β-secretase and/or the γ-secretase have potential in the treatment of Alzheimer's disease. Despite the importance of the β-secretase and γ-secretase in the pathogenic processing of APP, molecular definition of these enzymes has not been accomplished to date. That is, it was not known what enzymes were required for cleavage at either the β-secretase or the γ-secretase cleavage site. The sites themselves were known because APP was known and the Aβ₁₋₄₂, peptide was known, see U.S. Pat. No. 5,766,846 and U.S. Pat. No. 5,837,672, (incorporated by reference, with the exception to reference to “soluble” peptides). But what enzyme was involved in producing the Aβ₁₋₄₂, peptide was unknown.

The present invention involves the molecular definition of several novel human aspartyl proteases and one of these, referred to as Hu-Asp-2(a) and Hu-Asp2(b) has been characterized in detail. Previous forms of asp1 and asp2 have been disclosed, see P 0848062 A2 and EP 0855444A2, inventors David Powel CL al., assigned to Smith Kline Beecham Corp. (incorporated by reference). Herein are disclosed old and new forms of Hu-Asp 2. For the first time they are expressed in active form, their substrates are disclosed, and their specificity is disclosed. Prior to this disclosure cell or cell extracts were required to cleave the β-secretase site, now purified protein can be used in assays also described here. Based on the results of (1) antisense knock out experiments, (2) transient transfection knock in experiments, and (3) biochemical experiments using purified recombinant Hu-Asp-2, we demonstrate that Hu-Asp-2 is the β-secretase involved in the processing of APP. Although the nucleotide and predicted amino acid sequence of Hu-Asp-2(a) has been reported, see above, see EP 0848062 A2 and EP 0855444A2Z no functional characterization of the enzyme was disclosed. Here the authors characterize the Hu-Asp-2 enzyme and are able to explain why it is a critical and essential enzyme required in the formation of Aβ₁₋₄₂, peptide and possible a critical step in the development of AD.

In another embodiment the present invention also describes a novel splice variant of Hu-Asp2, referred to as Hu-Asp-2(b), that has never before been disclosed.

In another embodiment, the invention provides isolated nucleic acid molecules comprising a polynucleotide encoding a polypeptide: selected from the group consisting of human aspartyl protease 1 (Hu-Asp1) and two alternative splice variants of human aspartyl protease 2 (Hu-Asp2), designated herein as Hu-Asp2(a) and Hu-Asp2(b). As used herein, all references to “Hu-Asp2” should be understood to refer to both Hu-Asp2(a) and Hu-Asp2(b). Hu-Asp1 is expressed most abundantly in pancreas and prostate tissues, while Hu-Asp2(a) and Hu-Asp2(b) am expressed most abundantly in pancreas and brain tissues. The invention also provides isolated Hu-Asp1, Hu-Asp2(a), and Hu-Asp2(b) polypeptides as well as fragments thereof which exhibit aspartyl protease activity.

The predicted amino acid sequences of Hu-Asp1, Hu-Asp2(a) and Hu-Asp2(b) share significant homology with previously identified mammalian aspartyl proteases such as pepsinogen A, pepsinogen B, cathepsin D, cathepsin E, and renin. P. B. Szecs, Scand. J. Clin. Lab. Invest. 52:(Suppl. 210 5-22 (1992)). These enzymes are characterized by the presence of a duplicated DTG/DSG sequence motif. The Hu-Asp1 and HuAsp2 polypeptides disclosed herein also exhibit extremely high homology with the ProSite consensus motif for aspartyl proteases extracted from the SwissProt database.

The nucleotide sequence given as residues 1-1554 of SEQ ID NO:1 corresponds to the nucleotide sequence encoding Hu-Asp1, the nucleotide sequence given as residues 1-1503 of SEQ ID NO:3 corresponds to the nucleotide sequence encoding Hu-Asp2(a), and the nucleotide sequence given as residues 1-1428 of SEQ ID NO:5 corresponds to the nucleotide sequence encoding Hu-Asp2(b). The isolation and sequencing of DNA encoding Hu-Asp1, Hu-Asp2(a), and Hu-Asp2(b) is described below in Examples 1 and 2.

As is described in Examples 1 and 2, automated sequencing methods were used to obtain the nucleotide sequence of Hu-Asp1, Hu-Asp2(a) and Hu-Asp-2(b). The Hu-Asp nucleotide sequences of the present invention were obtained for both DNA strands, and are believed to be 100% accurate. However, as is known in the art, nucleotide sequence obtained by such automated met may contain some errors. Nucleotide sequences determined by automation are typically at least about 90%, more typically at least about 95% to at least about 99.9% identical to the actual nucleotide sequence of a given nucleic acid molecule. The actual sequence may be more precisely determined using manual sequencing methods, which are well known in the art. An error in sequence which results in an insertion or deletion of one or more nucleotides may result in a time shift in translation such that the predicted amino acid sequence will differ from that which would be predicted from the actual nucleotide sequence of the nucleic acid molecule, starting at the point of the mutation. The Hu-Asp DNA of the present invention includes cDNA, chemically synthesized DNA, DNA isolated by PCR, genomic DNA, and combinations thereof. Genomic Hu-Asp DNA may be obtained by screening a genomic library with the Hu-Asp2 cDNA described herein, using methods that are well known in the art, or with oligonucleotides chosen from the Hu-Asp2 sequence that will prime the polymerase chain reaction (PCR). RNA transcribed from Hu-Asp DNA is also encompassed by the present invention.

Due to the degeneracy of the genetic code, two DNA sequences may differ and yet encode identical amino acid sequences. The present invention thus provides isolated nucleic acid molecules having a polynucleotide sequence encoding any of the Hu-Asp polypeptides of the invention, wherein said polynucleotide sequence encodes a Hu-Asp polypeptide having the complete amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, or fragments thereof.

Also provided herein are purified Hu-Asp polypeptides, both recombinant and non-recombinant. Most importantly, methods to produce Hu-Asp2 polypeptides in active form are provided. These include production of Hu-Asp2 polypeptides and variants thereof in bacterial cells, insect cells, and mammalian cells, also in forms that allow secretion of the Hu-Asp2 polypeptide from bacterial, insect or mammalian cells into the culture medium, also methods to produce variants of Hu-Asp2 polypeptide incorporating amino acid tags that facilitate subsequent purification. In a preferred embodiment of the invention the Hu-Asp2 polypeptide is converted to a proteolytically active form either in transformed cells or after purification and cleavage by a second protease in a cell-free system, such active forms of the Hu-Asp2 to polypeptide beginning with the N-ten al sequence TQHGIR or ETDEEP. Variants and derivatives, including rents, of Hu-Asp proteins having the native amino acid sequences given in SEQ ID Nos: 2, 4, and 6 that retain any of the biological activities of Hu-Asp are also within the scope of the present invention. Of course one of ordinary skill in the art will really be able to determine whether a variant, derivative, or fragment of a Hu-Asp protein displays Hu-Asp activity by subjecting the variant, derivative, or fragment to a standard aspartyl protease assay. Fragments of Hu-Asp within the scope of this invention include those that contain the active site domain containing the amino acid sequence DTG, fragments that contain the active site domain amino acid sequence DSG, fragments containing both the DTG and DSG active site sequences, fragments in which the spacing of the DTG and DSG active site sequences has been lengthened, fragments in which the spacing has been shortened. Also within the scope of the invention are fragments of Hu-Asp in which the transmembrane domain has been removed to allow production of Hu-Asp2 in a soluble form. In another embodiment of the invention, the two halves of Hu-Asp2, each containing a single active site DTG or DSG sequence can be produced independently as recombinant polypeptides, then combined in solution where they reconstitute an active protease.

Hu-Asp variants may be obtained by mutation of native Hu-Asp-encoding nucleotide sequences, for example. A Hu-Asp variant, as referred to herein, is a polypeptide substantially homologous to a native Hu-Asp polypeptide but which has an amino acid sequence different from that of native Hu-Asp because of one or more deletions, insertions, or substitutions in the amino acid sequence. The variant amino acid or nucleotide sequence is preferably at least about 80% identical, more preferably at least about 90% identical, and most preferably at least about 95% identical, to a native Hu-Asp sequence. Thus, a variant nucleotide sequence which contains, for example, 5 point mutations for every one hundred nucleotides, as compared to a native Hu-Asp gene, will be 95% identical to the native protein. The percentage of sequence identity, also termed homology, between a native and a variant Hu-Asp sequence may also be determined, for example, by comparing the two sequences using any of the computer programs commonly employed for this purpose, such as the Gap program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, Madison Wis.), which uses the algorithm of Smith and Waterman (Adv. Appl. Math 2: 482489 (1981)).

Alterations of the native amino acid sequence may be accomplished by any of a number of known techniques. For example, mutations may be introduced at particular locations by procedures well known to the skilled ardsan, such as oligonucleotide-directed mutagenesis, which is described by Walder et al (Gene 42:133 (1986)); Bauer et at. (Gene 37:73 (1985)); Craik (BioTechniques, January 1985, pp. 12-19); Smith et al. (Genetic Engineering: Principles and Methods, Plenum Press (1981)); and U.S. Pat. Nos. 4,518,584 and 4,737,462.

Hu-Asp variants within the scope of the invention may comprise conservatively substituted sequences, meaning that one or more amino acid residues of a Hu-Asp polypeptide are replaced by different residues that do not alter the secondary and/or tertiary structure of the Hu-Asp polypeptide. Such substitutions may include the replacement of an amino acid by a residue having similar physicochemical properties, such as substituting one aliphatic residue (Ile, Val, Leu or Ala) for another, or substitution between basic residues Lys and Arg, acidic residues Glu and Asp, amide residues Gin and Asn, hydroxyl residues Ser and Tyr, or aromatic residues Phe and Tyr. Further information regarding making phenotypically silent amino acid exchanges may be found in Bowie et al, Science 247:1306-1310 (1990). Other Hu-Asp variants which might retain substantially the biological activities of Hu-Asp are those where amino acid substitutions have been made in areas outside functional regions of the protein.

In another aspect, the invention provides an isolated nucleic acid molecule comprising a polynucleotide which hybridizes under stringent conditions to a portion of the nucleic acid molecules described above, e.g., to at least about 15 nucleotides, preferably to at least about 20 nucleotides, more preferably to at least about 30 nucleotides, and still more preferably to at least about from 30 to at least about 100 nucleotides, of one of the previously described nucleic acid molecules. Such portions of nucleic acid molecules having the described lengths refer to, e.g., at least about 15 contiguous nucleotides of the reference nucleic acid molecule. By stringent hybridization conditions is intended overnight incubation at about 42° C. for about 2.5 hours in 6×SSC/0.1% SDS, followed by washing of the filters in 1.0×SSC at 65° C., 0.1% SDS.

Fragments of the Hu-Asp-encoding nucleic acid molecules described herein, as well as polynucleotides-capable of hybridizing to such nucleic acid molecules may be used as a probe or as primers in a polymerase chain reaction (PCR). Such probes may be used, e.g., to detect the presence of Hu-Asp nucleic acids in in vitro assays, as well as in Southern and northern blots. Cell types expressing Hu-Asp may also be identified by the use of such probes. Such procedures are well known, and the skilled artisan will be able to choose a probe of a length suitable to the particular application. For PCR, 5′ and 3′ primers corresponding to the termini of a desired Hu-Asp nucleic acid molecule are employed to isolate and amplify that sequence using conventional techniques.

Other useful fragments of the Hu-Asp nucleic acid molecules are antisense or sense oligonucleotides comprising a single-stranded nucleic acid sequence capable of binding to a target Hu-Asp mRNA (using a sense strand), or Hu-Asp DNA (using an antisense strand) sequence. In a preferred embodiment of the invention these Hu-Asp antisense oligonucleotides reduce Hu-Asp mRNA and consequent production of Hu-Asp polypeptides.

In another aspect, the invention includes Hu-Asp polypeptides with or without associated native pattern glycolation. Both-Hu-Asp1 and Hu-Asp2 have canonical acceptor sites for Asn-linked sugars, with Hu-Asp1 having two of such sites, and Hu-Asp2 having four. Hu-Asp expressed in yeast or mammalian expression systems (discussed below) may be similar to or significantly different from a native Hu-Asp polypeptide in molecular weight and glycosylation pattern. Expression of Hu-Asp in bacterial expression systems will provide non-glycosylated Hu-Asp.

The polypeptides of the present invention are preferably provided in an isolated form, and preferably are substantially purified. Hu-Asp polypeptides may be recovered and purified from tissues, cultured cells, or recombinant cell cultures by well-known methods, including ammonium sulfate or ethanol precipitation, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography, lectin chromatography, and high performance liquid chromatography (HPLC). In a preferred embodiment, an amino acid tag is added to the Hu-Asp polypeptide using genetic engineering techniques that are well known to practioners of the art which include addition of six histidine amino acid residues to allow purification by binding to nickel immobilized on a suitable support epitopes for polydonal or monoclonal antibodies including but not limited to the T7 epitope, the myc epitope, and the V5a epitope, and fusion of Hu-Asp2 to suitable protein partners including but not limited to glutathione-S-transferase or maltose binding protein. In a preferred embodiment these additional amino acid sequences are added to the C-terminus of Hu-Asp but may be added to the N-terminus or at intervening positions within the Hu-Asp2 polypeptide.

The present invention also relates to vectors comprising the polynucleotide molecules of the invention, as well as host cell transformed with such vectors. Any of the polynucleotide molecules of the invention may be joined to a vector, which generally includes a selectable marker and an origin of replication, for propagation in a host. Because the invention also provides Hu-Asp polypeptides expressed from the polynucleotide molecules described above, vectors for the expression of Hu-Asp are preferred. The vectors include DNA encoding any of the Hu-Asp polypeptides described above or below, operably linked to suitable transcriptional or translational regulatory sequences, such as those derived from a mammalian, microbial, viral, or insect gene. Examples of regulatory sequences include transcriptional promoters, operators, or enhancers, mRNA ribosomal binding sites, and appropriate sequences which control transcription and translation. Nucleotide sequences are operably linked when the regulatory sequence functionally relates to the DNA encoding Hu-Asp. Thus, a promoter nucleotide sequence is operably linked to a Hu-Asp DNA sequence if the promoter nucleotide sequence directs the transcription of the Hu-Asp sequence.

Selection of suitable vectors to be used for the cloning of polynucleotide molecules encoding Hu-Asp1, or for the expression of Hu-Asp polypeptides, will of course depend upon the host cell in which the vector will be transformed, and where applicable, the host cell from which the Hu-Asp polypeptide is to be expressed Suitable host cells for expression of Hu-Asp polypeptides include prolacyotes, yeast, and higher eukaryotic cells, each of which is discussed below.

The Hu-Asp polypeptides to be expressed in such host cells may also be fusion proteins which include regions from heterologous proteins. Such regions may be included to allow, e.g., secretion, improved stability, or facilitated purification of the polypeptide. For example, a sequence encoding an appropriate signal peptide can be incorporated into expression vectors. A DNA sequence for a signal peptide (secretory leader) may be fused in-frame to the Hu-Asp sequence so that Hu-Asp is translated as a fusion protein comprising the signal peptide. A signal peptide that is functional in the intended host cell promotes extracellular secretion of the Hu-Asp polypeptide. Preferably, the signal sequence will be cleaved from the Hu-Asp polypeptide upon secretion of Hu-Asp from the cell. Non-limiting examples of signal sequences that can be used in practicing the invention include the yeast I-factor and the honeybee melatin leader in sf9 insect cells.

In a preferred embodiment the Hu-Asp polypeptide will be a fusion protein which includes a heterologous region used to facilitate purification of the polypeptide. Many of the available peptides used for such a function allow selective binding of the fusion protein to a binding partner. For example, the Hu-Asp polypeptide may be modified to comprise a peptide to form a fusion protein which specifically binds to a binding partner, or peptide tag Non-limiting examples of such peptide tags include the 6-His tag, thioredoxin tag, hemaglutinin tag, GST tag, and OmpA signal sequence tag. As will be understood by one of skill in the art, the binding partner which recognizes and binds to the peptide may be any molecule or compound including metal ions (e.g., metal affinity columns), antibodies, or fragments thereof, and any protein or peptide which binds the peptide, such as the FLAG tag.

Suitable host cells for expression of Hu-Asp polypeptides includes prokaryotes, yeast, and higher eukaryotic cells. Suitable prokaryotic hosts to be used for the expression of Hu-Asp include bacteria of the genera Escherichia, Bacillus, and Salmonella, as well as members of the genera Pseudomonas, Streptomyces, and Staphylococus. For expression in, e.g., E coli, a Hu-Asp polypeptide may include an N-terminal methionine residue to facilitate expression of the recombinant polypeptide in a prokaryotic host. The N-terminal Met may optionally then be cleaved from the expressed Hu-Asp polypeptide. Other N-terminal amino acid residues can be added to the Hu-Asp polypeptide to facilitate expression in Escherichia coli including but not limited to the 17 leader sequence; the T7-caspase 8 leader sequence, as well as others leaders including tags for purification such as the 6-His tag (Example 9). Hu-Asp polypeptides expressed in E. coli may be shortened by removal of the cytoplasmic tail the transmembrane domain, or the membrane proximal region. Hu-Asp polypeptides expressed in E coli may be obtained in either a soluble form or as an insoluble form which may or may not be present as an inclusion body. The insoluble polypeptide may be rendered soluble by guanidine HCl, urea or other protein denaturants, then refolded into a soluble form before or after purification by dilution or dialysis into a suitable aqueous buffer. If the inactive proform of the Hu-Asp was produced using recombinant methods, it may be rendered active by cleaving off the prosegment with a second suitable protease such as human immunodeficiency virus protease.

Expression vectors for use in prokaryotic hosts generally comprises one or more phenotypic selectable marker genes. Such genes generally encode, e.g., a protein that confers antibiotic resistance or that supplies an auxotrophic requirement A wide variety of such vectors are-readily available from commercial sources. Examples include pSPORT vectors, pGEM vectors (Promega), pPROEX vectors (LTI, Bethesda, Md.), Bluescript vectors (Stratagene), pET vectors (Novagen) and pQE vectors (Qiagen).

Hu-Asp may also be expressed in yeast host cells from genera including Saccharomyces, Pichia, and Kluveromyces. Preferred yeast hosts are S. cerevisiae and P. pastoris. Yeast vectors will often contain an origin of replication sequence from a 2T yeast plasmid, an autononously replicating sequence (ARS), a promoter region, sequences for polyadenylation, sequences for transcription termination, and a selectable marker gene. Vectors replicable in both yeast and E coli (termed shuttle vectors) may also be used. In addition to the above-mentioned features of yeast vectors, a shuttle vector will also include sequences for replication and selection in E. coli. Direct secretion of Hu-Asp polypeptides expressed in yeast hosts may be accomplished by the inclusion of nucleotide sequence encoding the yeast 1-factor leader sequence at the 5′ end of the Hu-Asp encoding nucleotide sequence.

Insect host cell culture systems may also be used for the expression of Hu-Asp polypeptides. In a preferred embodiment, the Hu-Asp polypeptides of the invention are expressed using an insect cell expression system (see Example 10). Additionally, a baculovirus expression system can be used for expression in insect cells as reviewed by Luckow and Summers, Bio/Technology 6:47 (1988).

In another preferred embodiment, the Hu-Asp polypeptide is expressed in mammalian host cells. Non-limiting examples of suitable mammalian cell lines include the COS-7 line of monkey kidney cells (Gluzman et al., Cell 23:175 (1981)), human embyonic kidney cell line 293, and Chinese hamster ovary (CHO) cells Preferably, Chinese hamster ovary (CHO) cells are used for expression of Hu-Asp proteins (Example 11).

The choice of a suitable expression vector for expression of the Hu-Asp polypeptides of the invention will of course depend upon the specific mammalian host cell to be used, and is within the skill of the ordinary artisan. Examples of suitable expression vectors include pcDNA3 (Invitrogen) and pSVL (Pharmacia Biotech). A preferred vector for expression of Hu-Asp polypeptides is pcDNA3.1-Hygro (Invitrogen). Expression vectors for use in mammalian host cells may include transcriptional and translational control sequences derived from viral genomes. Commonly used promoter sequences and enhancer sequences which may be used in the present invention include, but are not limited to, those derived from human cytomegalovirus (CMV). Adenovirus 2, Polyoma virus, and Simian virus 40 (SV40). Methods for the construction of mammalian expression vectors are disclosed, for example, in Okayama and Berg (Mol. Cell. Biol. 3:280 (1983)); Cosman et al. (Mol. Immunol. 23:935 (1986)); Cosman et al. (Nature 312:768 (1984)); EP-A-0367566; and WO 91/18982.

The polypeptides of the present invention may also be used to raise polyclonal and monoclonal antibodies, which arm useful: in diagnostic assays for detecting Hu-Asp polypeptide expression. Such antibodies may be prepared by conventional techniques. See, for example, Antibodies: A Laboratory Manual, Harlow and Land (eds.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.,; (1988); Monoclonal Antibodies, Hybridomas: A New Dimension in Biological Analyses, Kennet et al. (eds.), Plenum Press, New York (1980). Synthetic peptides comprising portions of Hu-Asp containing 5 to 20 amino acids may also be used for the production of polyclonal or monoclonal antibodies after linkage to a suitable carrier protein including but not limited to keyhole limpet himacyanin (K1H), chicken ovalbumin, or bovine serum albumin using various cross-linking rents including carbodimides, glutaraldehyde, or if the peptide contains a cysteine, N-methmaleimide. A preferred peptide for immunization when conjugated to KLH contains the C-terminus of Hu_Asp1 or Hu-Asp2 comprising QRRPRDPEVVNDESSLVRHRWK or LRQQHDDFADDISLLK respectively.

The Hu-Asp nucleic acid molecules of the present invention are also valuable for chromosome identification, as they can hybridize with a specific location on a human chromosome. Hu-Asp1 has been localized to chromosome 21, while Hu-Asp2 has been localized to chromosome 11q233-24.1. There is a current need for identifying particular sites on the chromosome, as few chromosome marking reagents based on actual sequence data (repeat polymorphisms) are presently available for marking chromosomal location. Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. The relationship between genes and diseases that have been mapped to the same chromosomal region can then be identified through linkage analysis, wherein the coinheritance of physically adjacent genes is determined. Whether a gene appearing to be related to a particular disease is in fact the cause of the disease can then be determined by comparing the nucleic acid sequence between affected and unaffected individuals. In another embodiment, the invention relates to a method of assaying Hu-Asp function, specifically Hu-Asp2 function which involves incubating in solution the Hu-Asp polypeptide with a suitable substrate including but not limited to a synthetic peptide containing the β-secretase cleavage site of APP, preferably one containing the mutation found in a Swedish kindred with inherited AD in which KM is changed to NL, such peptide comprising the sequence SEVNLDAEFR in an acidic buffering solution, preferably an acidic buffering solution of pH5.5 (see Example 12) using cleavage of the peptide monitored by high performance liquid chromatography as a measure of Hu-Asp proteolytic activity. Preferred assays for proteolytic activity utilize internally quenched peptide assay substrates. Such suitable substrates include peptides which have attached a paired flurophore and quencher including but not limited to coumarin and dinitrophenol, respectively such that cleavage of the peptide by the Hu-Asp results in increased fluorescence due to physical separation of the flurophore and quencher. Preferred calorimetric assays of Hu-Asp protelytic activity utilize other suitable substrates that include the P2 and P1 amino acids comprising the recognition site for cleavage linked to o-nitrophenol through an amide linkage, such that cleavage by the Hu-Asp results in an increase in optical density after altering the assay buffer to alkaline pH.

In another embodiment, the invention relates to a method for the identification of an agent that increases the activity of a Hu-Asp polypeptide selected from the group consisting of Hu-Asp1, Hu-Asp2(a), and Hu-Asp2(b), the method comprising

-   -   (a) determining the activity of said Hu-Asp polypeptide in the         presence of a test agent and in the absence of a test agent; and     -   (b) comparing the activity of said Hu-Asp polypeptide determined         in the presence of said test agent to the activity of said         Hu-Asp polypeptide determined in the absence of said test agent;         whereby a higher level of activity in the presence of said test         agent than in the absence of said test agent indicates that said         test agent has increased the activity of said Hu-Asp         polypeptide. Such tests can be performed with Hu-Asp polypeptide         in a cell free system and with cultured cells that express         Hu-Asp as well as variants or isoforms thereof.

In another embodiment, the invention relates to a method for the identification of an agent that decreases the activity of a Hu-Asp polypeptide selected from the group consisting of Hu-Asp1. Hu-Asp2(a), and Hu-Asp2(b), the method comprising

-   -   (a) determining the activity of said Hu-Asp polypeptide in the         presence of a test agent and in the absence of a test agent; and     -   (b) comparing the activity of said Hu-Asp polypeptide determined         in the presence of said test agent to the activity of said         Hu-Asp polypeptide determined in the absence of said test agent;         whereby a lower level of activity in the presence of said test         agent than in the absence of said test agent indicates that said         test agent has decreased the activity of said Hu-Asp         polypeptide. Such tests can be performed with Hu-Asp         polypeptide, in a cell free system and with culture cells that         express Hu-Asp as well as variants or isoforms thereof.

In another embodiment, the invention relates to a novel cell line (HEK2.3 cells) for measuring processing of amyloid β peptide (Aβ) from the amyloid protein precursor (APP). The cells are stable transformants of human embryonic kidney 293 cells (HEK293) with a bicistronic vector derived from pIRES-EGFP (Clontech) containing a modified human APP cDNA, an internal ribosome entry site and an enhanced green fluorescent protein (EGFP) cDNA in the second cistron. The APP cDNA was modified by adding two lysine codons to the carboxyl terminus of the APP coding sequence. This increases processing of Aβ peptide from human APP by 24 fold. This level of Aβ peptide processing is 60 fold higher than is seen in nontransformed HEK293 cells. HEK125.3 cells will be useful for assays of compounds that inhibit Aβ peptide processing. This invention also includes addition of two lysine residues to the C-terminus of other APP isoforms including the 751 and 770 amino acid isoforms, to isoforms of APP having mutations found in human AD including the Swedish KM→NL and V717→F mutations, to C-terminal fragments of APP, such as those beginning with the β-secretase cleavage site, to C-terminal fragments of APP containing the β-secretase cleavage site which have been operably linked to an N-terminal signal peptide for membrane insertion and secretion, and to C-terminal fragments of APP which have been operably linked to an N-terminal signal peptide for membrane insertion and secretion and a reporter sequence including but not limited to green fluorescent protein or alkaline phosphatase, such that β-secretase cleavage releases the reporter protein from the surface of cells expressing the polypeptide.

Having generally described the invention, the same will be more really understood by reference to the following examples, which are provided by way of illustration and are not intended as limiting.

EXAMPLES Example 1 Development of a Search Algorithm Useful for the Identification of Aspartyl Proteases, and Identification of C. elegans Aspartyl Protease Genes in Wormpep12:

Materials and Methods:

Classical aspartyl proteases such as pepsin and renin possess a two-domain structure which folds to bring two aspartyl residues into proximity within the active site. These are embedded in the short tripeptide motif DTG, or more rarely. DSG. The DTG or DSG active site motif appears at about residue 25-30 in the enzyme, but at about 65-70 in the proenzyme (prorenin, pepsinogen). This motif appears again about 150-200 residues downstream. The proenzyme is activated by cleavage of the N-terminal prodomain. This pattern exemplifies the double domain structure of the modern day aspartyl enzymes which apparently arose by gene duplication and divergence. Thus; NH₂-X-D²⁵TG-Y-D^(Y+25)TG-C where X denotes the beginning of the enzyme, following the N-terminal prodomain, and Y denotes the center of the molecule where the gene repeat begins again.

In the case of the retroviral enzymes such as the HIV protease, they represent only a half of the two-domain structures of well-known enzymes like pepsin, cathepsin D, renin, etc. They have no prosegment, but are carved out of a polyprotein precursor containing the gag and pol proteins of the virus. They can be represented by: NH₂-D²⁵TG-C100 This “monomer” only has about 100 aa, so is extremely parsimonious as compared to the other aspartyl protease “dimers” which have of the order of 330 or so aa, not counting the N-terminal prodomain.

The limited length of the eukaryotic aspartyl protease active site motif makes it difficult to search EST collections for novel sequences. EST sequences typically average 250 nucleotides, and so in this case would be unlikely to span both aspartyl protease active site motifs. Instead, we turned to the C. elegans genome. The C. elegant genome is estimated to contain around 13,000 genes. Of these, roughly 12,000 have been sequenced and the corresponding hypothetical open reading frame (ORF) has been placed in the database Wormpep12. We used this database as the basis for a whole genome scan of a higher eukaryote for novel aspartyl proteases, using an algorithm that we developed specifically for this purpose. The following AWK script for locating proteins containing two DTG or DSG motifs was used for the search, which was repeated four times to recover all pairwise combinations of the aspartyl motif. BEGIN{RS=“>”} /* defines “>” as record separator { for FASTA format */ pos = index($0,“DTG”) /*finds “DTG” in record*/ if (pos>0) {  rest = substr($0,pos+3) /*get rest of record after first DTG*/  pos2 = index(rest,“DTG”) /*find second DTG*/  if (pos2>0) printf (“%s%s\n”,“>”,$0)} /*report hits*/ } }

The AWK script shown above was used to search Wormpep12, which was downloaded from ftp.sanger.ac.uk/pub/databases/wormpep, for sequence entries containing at least two DTG or DSG motifs. Using AWK limited each record to 3000 characters or less. Thus, 35 or so larger records were eliminated manually from Wormpep12 as in any case these were unlikely to encode aspartyl proteases.

Results and Discussion:

The Wormpep12 database-contains 12,178 entries, although some of these (<10%) represent alternatively spliced transcripts from the same gene. Estimates of the number of genes encoded in the C. elegans genome is on the order of 13,000 genes, so Wormpep12 may be estimated to cover greater-than 90% of the C. elegans genome.

Eukaryotic aspartyl proteases contain a two-domain structure, probably arising from ancestral gene duplication. Each domain contains the active site motif D(S/T)G located from 20-25 amino acid residues into each domain. The retroviral (e.g., HIV protease) or retrotransposon proteases are homodimers of subunits which are homologous to a single eukaryotic aspartyl protease domain. An AWK script was used to search the Wormpep12 database for proteins in which the D(S/T)G motif occurred at least twice. This identified >60 proteins with two DTG or DSG motifs. Visual inspection was used to select proteins in which the position of the aspartyl domains was suggestive of a two-domain structure meeting the criteria described above.

In addition, the PROSITE eukaryotic and viral aspartyl protease active site pattern PS00141 was used to search Wormpep12 for candidate aspartyl proteases. (Bairoch A., Bucher P., Hofmann K, The PROSITE database: its status in 1997, Nucleic Acids Res. 24:217-221(1997)). Tis generated an overlapping set of Wormpep12 sequences. Of these, active site pattern. Of these seven, three were found in the same cosmid clone (F21F83, F21F8.4, and F21F8.7) suggesting that they represent a family of proteins that arose by ancestral gene duplication. Two other ORFs with extensive homology to F21F8.3, F21F8A and F21F8.7 are present in the same gene cluster (F21F8.2 and F21F8.6), however, these contain only a single DTG motif Exhaustive BLAST searches with these seven sequences against Wormpep 12 failed to reveal additional candidate aspartyl proteases in the C. elegans genome containing two repeats of the DTG or DSG motif.

BLASTX search with each C. elegans sequence against SWISS-PROT, GenPep and TREMBL revealed that R12H7.2 was the closest worm homologue to the known mammalian aspartyl proteases, and that T18H9.2 was somewhat more distantly related, while CEASP1, F21F8.3, F21F8.4, and F21F8.7 formed a subcluster which had the least sequence homology to the mammalian sequences.

Discussion:

APP, the presenilins, and p35, the activator of cdk5, all undergo intracellular proteolytic processing at sites which conform to the substrate specificity of the HIV protease. Dysregulation of a cellular aspartyl protease with the same substrate specificity, might therefore provide a unifying mechanism for causation of the plaque and tangle pathologies in AD. Therefore, we sought to identify novel human aspartyl proteases. A whole genome scan in C. elegans identified seven open reading frames that adhere to the aspartyl protease profile that we had identified. These seven aspartyl proteases probably comprise the complete complement of such proteases in a simple, multicellular eukaryote. These include four closely related aspartyl proteases unique to C. elegans which probably arose by duplication of an ancestral gene. The other three candidate aspartyl proteases (T18H9.2, R12H7.2 and C11D2.2) were found to have homology to mammalian gene sequences.

Example 2 Identification of Novel Human Aspartyl Proteases Using Database Mining by Genome Bridging

Materials and Methods:

Computer-Assisted Analysis of EST Databases, cDNA, and Predicted Polypeptide Sequences:

Exhaustive homology searches of EST databases with the CEASP1, F21F8.3, F21F8A, and F21F8.7 sequences failed to reveal any novel mammalian homologues. TBLASTN searches with R12H7.2 showed homology to cathepsin D, cathepsin E, pepsinogen A, pepsinogen C and renin, particularly around the DTG motif within the active site, but also failed to identify any additional novel mammalian aspartyl proteases. This indicates that the C. elegans genome probably contains only a single lysosomal aspartyl protease which in mammals is represented by a gene family that arose through duplication and consequent modification of an ancestral gene.

TBLASTN searches with T18H9.2, the remaining C. elegans sequence, identified several ESTs which assembled into a contig encoding a novel human aspartyl protease (Hu-ASP1). As is described above in Example 1, BLASTX search with the Hu-ASP1 contig against SWISS-PROT revealed that the active site motifs in the sequence aligned with the active sites of other aspartyl proteases. Exhaustive, repetitive rounds of BLASTN searches against LifeSeq, LifeSeqFL, and the public EST collections identified 102 EST from multiple cDNA libraries that assembled into a single contig. The 51 sequences in this contig found in public EST collections also have been assembled into a single contig (THC213329) by The Institute for Genome Research (TIGR). The TIGR annotation indicates that they failed to find any hits in the database for the contig. Note that the TIGR contig is the reverse complement of the LifeSeq contig that we assembled. BLASTN search of Hu-ASP1 against the rat and mouse EST sequences in ZooSeq revealed one homologous EST in each database (Incyte clone 700311523 and IMAGE clone 313341, GenBank accession number W10530, respectively).

TBLASTN searches with the assembled DNA sequence for Hu-ASP1 against both LifeSeqFL and the public EST databases identified a second, related human sequence (Hu-Asp2) represented by a single EST (2696295). Translation of this partial cDNA sequence reveals a single DTG motif which has homology to the active site motif of a bovine aspartyl protease, NM1.

BLAST searches, contig assemblies and multiple sequence alignments were performed using the bioinformatics tools provided with the LifeSeq, LifeSeqFL and LifeSeq Assembled databases from Incyte. Predicted protein motifs were identified using either the ProSite dictionary (Motifs in GCG 9) or the Pfam database.

Full-Length cDNA Cloning of Hu-Asp1

The open reading frame of C. elegans gene T18H9.2CE was used to query Incyte LifeSeq and LifeSeq-FL databases and a single electronic assembly referred to as 1863920CE1 was detected. The 5′ most cDNA clone in this contig, 1863920, was obtained from Incyte and completely sequenced on both strands. Translation of the open reading frame contained within clone 1863920 revealed the presence of the duplicated aspartyl protease active site motif (DTG/DSG) but the 5′ end was incomplete. The remainder of the Hu-Asp1 coding sequence was determined by 5′ Marathon RACE analysis using a human placenta Marathon ready cDNA template (Clonetech). A 3′-antisense oligonucleotide primer specific for the 5′ end of clone 1863920 was paired with the 5′-sense primer specific for the Marathon ready cDNA synthetic adaptor in the PCR. Specific PCR products were directly sequenced by cycle sequencing and the resulting sequence assembled with the sequence of clone 1863920 to yield the complete coding sequence of Hu-Asp-1 (SEQ ID No.1).

Several interesting features are present in the primary amino acid sequence of Hu-Asp1 (FIG. 1, SEQ ID No. 2). The sequence contains a signal peptide (residues 1-20 in SEQ ID No. 2), a pro-segment, and a catalytic domain containing two copies of the aspartyl protease active site motif (DTG/DSG). The spacing between the first and second active site motifs is about 200 residues which should correspond to the expected size of a single, eukaryotic aspartyl protease domain. More interestingly, the sequence contains a predicted transmembrane domain (residues 469492 in SEQ ID No.2) near its C-terminus which suggests that the protease is anchored in the membrane. This feature is not found in any other aspartyl protease.

Cloning of a Full-Length Hu-Asp-2 cDNAs:

As is described above in Example I, genome wide scan of the Caenorhabditis elegans database Wormpep12 for putative aspartyl proteases and subsequent mining of human EST databases revealed a human ortholog to the C. elegans gene T18H9.2 referred to as Hu-Asp1. The assembled contig for Hu-Asp1 was used to query for human paralogs using the BLAST search tool in human EST databases and a single significant match (2696295CE1) with approximately 60% shared identity was found in the LifeSeq FL database. Similar queries of either gb105PubEST or the family of human databases available from TIGR did not identify similar EST clones. cDNA clone 2696295, identified by single pass sequence analysis from a human uterus cDNA library, was obtained from Incyte and completely sequence on both strands. This clone contained an incomplete 1266 bp open-reading frame that encoded a 422 amino acid polypeptide but lacked an initiator ATG on the 5′ end. Inspection of the predicted sequence revealed the presence of the duplicated aspartyl protease active site motif DTG/DSG, separated by 194 amino acid residues. Subsequent queries of later releases of the LifeSeq EST database identified an additional ESTs, sequenced from a human astrocyte cDNA library (4386993), that appeared to contain additional 5′ sequence relative to clone 2696295. Clone 4386993 was obtained from Incyte and completely sequenced on both strands. Comparative analysis of clone 4386993 and clone 2696295 confirmed that clone 4386993 extended the open-reading frame by 31 amino acid residues including two in-frame translation initiation codons. Despite the presence of the two in frame ATGs, no in-frame stop codon was observed upstream of the ATG indicating that the 4386993 may not be full-length. Furthermore, alignment of the sequences of clones 2696295 and 4386993 revealed a 75 base pair insertion in clone 2696295 relative to clone 4386993 that results in the insertion of 25 additional amino acid residues in 2696295. The remainder of the Hu-Asp2 coding sequence was determined by 5′ Marathon RACE analysis using a human hippocampus Marathon ready cDNA template (Clonetech). A 3′-antisense oligonucleotide primer specific for the shared 5′-region of clones 2696295 and 4386993 was-paired with the 5′-sense primer specific for the Marathon ready cDNA synthetic adaptor in the PCR-Specific PCR products were directly sequenced by cycle sequencing and the resulting sequence assembled with the sequence of clones 2696295 and 4386993 to yield the complete coding sequence of Hu-Asp2(a) (SEQ ID No. 3) and Hu-Asp2(b) (SEQ ID No. 5), respectively.

Several interesting features are present in the primary amino acid sequence of Hu-Asp2(a) (FIG. 2 and SEQ ID No. 4) and Hu-Asp-2(b) (FIG. 3, SEQ ID No. 6). Both sequences contain a signal peptide (residues 1-21 in SEQ ID No. 4 and SEQ ID No. 6), a pro-segment, and a catalytic domain containing two copies of the aspartyl protease active site motif (DTG/DSG). The spacing between the first and second active site motifs is variable due to the 25 amino acid residue deletion in Hu-Asp-2(b) and consists of 168-versus-194 amino acid residues, for Hu-Asp2(b) and Hu-Asp-2(a), respectively. More interestingly, both sequences contains a predicted transmembrane domain (residues 455-477 in SEQ ID No.4 and 430-452 in SEQ ID No. 6) near their C-termini which indicates that the protease is anchored in the membrane. This feature is not found in any other aspartyl protease except Hu-Asp1.

Example 3 Molecular Cloning of Mouse Asp2 cDNA and Genomic DNA.

Cloning and characterization of murine Asp2 cDNA—The murine ortholog of Hu_Asp2 was cloned using a combination of cDNA library screening, PCR, and genomic cloning. Approximately 500,000 independent clones from a mouse brain cDNA library were screened using a ³²P-labeled coding sequence probe prepared from Hu-Asp2. Replicate to positives were subjected to DNA sequence analysis and the longest cDNA contained the entire 3′ untranslated region and 47 amino acids in the coding region. PCR amplification of the same mouse brain cDNA library with an antisense oligonucleotide primer specific for the 5′-most cDNA sequence determined above and a sense primer specific for the 5′ region of human Asp2 sequence followed by DNA sequence analysis gave an additional 980 bp of the coding sequence. The remainder of the 5′ sequence of murine Asp-2 was derived from genomic sequence (see below).

Isolation and sequence analysis of the murine Asp-2 gene—A murine EST sequence encoding a portion of the murine Asp2 cDNA was identified in the GenBank EST database using the BLAST search tool and the Hu-Asp2 coding sequence as the query. Clone g3160898 displayed 88% shared identity to the human sequence over 352 bp. Oligonucleotide primer pairs specific for this region of murine Asp2 were then synthesized and used to amplify regions of the murine gene. Murine genomic DNA, derived from strain 129/SvJ, was amplified in the PCR (25 cycles) using various primer sets specific for murine Asp2 and the products analyzed by agarose gel electrophoresis. The primer set Zoo- and Zoo-4 amplified a 750 bp fragment that contained approximately 600 bp of intron sequence based on comparison to the known cDNA sequence. This primer set was then used to screen a murine BAC library by PCR, a single genomic clone was isolated and this cloned was confirmed contain the murine Asp2 gene by DNA sequence analysis. Shotgun DNA sequencing of this Asp2 genomic clone and comparison to the cDNA sequences of both Hu_Asp2 and the partial murine cDNA sequences defined the full-length sequence of murine Asp2 (SEQ ID No. 7). The predicted amino acid sequence of murine Asp2 (SEQ ID No. 8) showed 96.4% shared identity (GCG BestFit algorithm) with 18/501 amino acid residue substitutions compared to the human sequence (FIG. 4).

Example 4 Tissue Distribution of Expression of Hu-Asp2 Transcripts:

Materials and Methods:

The tissue distribution of expression of Hu-Asp2 was determined using multiple tissue Northern blots obtained from Clonetech (Palo Alto, Calif.). Incyte clone 2696295 in the vector pINCY was digested to completion with EcoRI/NotI and the 1.8 kb cDNA insert purified by preparative agarose gel electrophoresis. This fragment was radiolabeled to a specific activity >1×10⁹ dpm/μg by random priming in the presence of [α-³²P-DATP] (>3000 Ci/mmol, Amersham, Arlington Heights, Ill.) and Klenow fragment of DNA polymerase L Nylon filters containing denatured, size fractionated poly A⁺ RNAs isolated from different human tissues were hybridized with 2×10⁶ dpm/ml probe in ExpressHyb buffer (Clonetech, Palo Alto, Calif.) for 1 hour at 68° C. and washed as recommended by the manufacture. Hybridization signals were visualized by autoradiography using BioMax XR film (Kodak, Rochester, N.Y.) with intensifying screens at −80° C.

Results and Discussion:

Limited information on the tissue distribution of expression of Hu-Asp-2 transcripts was obtained from database analysis due to the relatively small number of ESTs detected using the methods described above (<5). In an effort to gain further information on the expression of the Hu-Asp2 gene, Northern analysis was employed to determine both the size(s) and abundance of Hu-Asp2 transcripts. PolyA⁺ RNAs isolated from a series of peripheral tissues and brain regions were displayed-on a solid support following separation under denaturing conditions and Hu-Asp2 transcripts were visualized by high stringency hybridization to radiolabeled insert from clone 2696295. The 2696295 cDNA probe visualized a constellation of transcripts that migrated with apparent sizes of 3.0 kb, 4.4 kb and 8.0 kb with the latter two transcript being the most abundant.

Across the tissues surveyed, Hu-Asp2 transcripts were most abundant in pancreas and brain with lower but detectable levels observed in all other tissues examined except thymus and PBLs. Given the relative abundance of Hu-Asp2 transcripts in brain, the regional expression in brain regions was also established. A similar constellation of transcript sizes were detected in all brain regions examined [cerebellum, cerebral cortex, occipital pole, frontal lobe, temporal lobe and putamen]with the highest abundance in the medulla and spinal cord.

Example 5 Northern Blot Detection of HuAsp-1 and HuAsp-2 Transcripts In Human Cell Lines:

A variety of human cell lines were tested for their ability to produce Hu-Asp1 and Asp2 mRNA. Human embryonic kidney (HEK-293) cells, African green monkey (Cos-7) cells, Chinese hamster ovary (CHO) cells, HELA cells, and the neuroblastoma cell line IMR-32 were all obtained from the ATCC; Cells were cultured in DME containing-10% FCS except CHO cells which were maintained in α-MEM 10% FCS at 37° C. in 5% CO₂ until they were near confluence. Washed monolayers of cells (3×10⁷) were lysed on the dishes and poly A⁺ RNA extracted using the Qiagen Oligotex Direct mRNA kit. Samples containing 21 μg of poly A⁺ RNA from each cell line were fractionated under denaturing conditions (glyoxal-treated), transferred to a solid nylon membrane support by capillary action, and transcripts visualized by hybridization with random-primed labeled (³²P) coding sequence probes derived from either Hu-Asp1 or Hu-Asp2. Radioactive signals were detected by exposure to X-ray film and by image analysis with a PhosphorImager.

The Hu-Asp1 cDNA probe visualized a similar constellation of transcripts (2.6 kb and 3.5 kb) that were previously detected is human tissues. The relative abundance determined by quantification of the radioactive signal was Cos-7>HEK 292=HELA >IMR32.

The Hu-Asp2 cDNA probe also visualized a similar constellation of transcripts compared to tissue (3.0 kb, 4.4 kb, and 8.0 kb) with the following relative abundance; HEK 293>Cos 7>1MR32>HELA.

Example 6 Modification of APP to Increase Aβ Processing for In Vitro Screening

Human cell lines that process Aβ peptide from APP provide a means to screen in cellular assays for inhibitors of β- and γ-secretase. Production and release of Aβ peptide into the culture supernatant is monitored by an enzyme-linked immunosorbent assay (EIA). Although expression of APP is widespread and both neural and non-neuronal cell lines process and release Aβ peptide, levels of endogenous APP processing am; low and difficult to detect by EIA. Aβ processing can be increased by expressing in transformed cell lines mutations of APP that enhance Aβ processing. We made the serendipitous observation that addition of two lysine residues to the carboxyl terminus of APP695 increases Aβ processing still further. This allowed us to create a transformed cell line that releases Aβ peptide into the culture medium at the remarkable level of 20,000 pg/ml.

Materials And Method

Materials:

Human embryonic kidney cell line 293 (HEK293 cells) were obtained internally. The vector pIRES-EGFP was purchased from Clontech. Oligonucleotides for mutation using the polymerase chain reaction (PCR) were purchased from Genosys. A plasmid containing human APP695 (SEQ ID No. 9 [nucleotide] and SEQ ID No. 10 [amino acid]) was obtained from Northwestern University Medical School. This was subcloned into pSK (Stratagene) at the NotI site creating the plasmid pAPP695.

Mutagenesis Protocol:

The Swedish mutation (K670N, M671L) was introduced into pAPP695 using the Stratagene Quick Change Mutagenesis Kit to create the plasmid pAPP695NL (SEQ ID No. 11 [nucleotide] and SEQ ID No. 12 [amino acid]). To introduce a di-lysine motif at the C-terminus of APP695, the forward primer #276 5′ GACTGACCACTCGACCAGGTRC (SEQ ID No.47) was used with the “patch” primer #274 5′ CGAATTAAATTCCAGCACACTGGCTACTTCTTGTTCTGCATCTCAAAGAAC (SEQ ID No. 48) and the flanking primer #275 CGAATTAAATTCCAGCACACTGGCTA (SEQ ID No. 49) to modify the 3′ end of the APP695 cDNA (SEQ ID No. 15 [nucleotide] and SEQ ID No. 16 [amino acid]). This also added a BstX1 restriction site that will be compatible with the BstX1 site in the multiple cloning site of pIRES-EGFP. PCR amplification was performed with a Clontech HF Advantage cDNA PCR kit using the polymerase mix and buffers supplied by the manufacturer. For “patch” PCR, the patch primer was used at {fraction (1/20)}th the molar concentration of the flanking primers. PCR amplification products were purified using a QIAquick PCR purification kit (Qiagen). After digestion with restriction enzymes, products were separated on 0.8% agarose gels and then excised DNA fragments were purified using a QIAquick gel extraction kit (Qiagen).

To reassemble a modified APP695-Sw cDNA, the 5′ NotI-Bgl2 fragment of the APP695-Sw cDNA and the 3′ Bgl2-BstX1 APP695 cDNA fragment obtained by PCR were ligated into pIRES-EGFP plasmid DNA opened at the NotI and BstX1 sites. Ligations were performed for 5 minutes at room temperature using a Rapid DNA Ligation kit (Boehringer Mannheim) and transformed into Library Efficiency DH5a Competent Cells (GibcoBRL Life Technologies). Bacterial colonies were screened for inserts by PCR amplification using primers #276 and #275. Plasmid DNA was purified for mammalian cell transfection using a QIAprep, Spin Miniprep kit (Qiagen). The construct obtained was designated pMG125.3 (APPSW-KK, SEQ ID No. 17 [nucleotide] and SEQ ID No. 18 [amino acid]).

Mammalian Cell Transfection:

HEK293 cells for transfection were grown to 80% confluence in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum Cotransfections were performed using LipofectAmine (Gibco-BRL) with 3 μg pMG 125.3 DNA and 9 μg pcDNA3.1 DNA per 10×10⁶ cells. Three days posttransfection, cells were passaged into medium containing G418 at a concentration of 400 ml. After three days growth in selective medium, cells were sorted by their fluorescence.

Clonal Selection of 125.3 Cells by FACS:

Cell samples were analyzed on an EPICS Elite ESP flow cytometer (Coulter, Hialeah, Fla.) equipped with a 488 nm excitation line supplied by an air-cooled argon laser. EGFP emission was through a 525 nm band-pass filter and fluorescence intensity was displayed on a 4-decade log scale after gating on viable cells as determined by forward and right angle light scatter. Single green cells were separated into each well of one 96 well plate containing growth medium without G418. After a four day recovery period. G418 was added to the medium to a final concentration of 400 μg/ml. After selection, 32% of the wells contained expanding clones. Wells with clones were expanded from the 96 well plate to a 24 well plate and then a 6 well plate with the fastest growing colonies chosen for expansion at each passage. The final cell line selected was the, fastest growing of the final six passaged. This clone, designated 125.3, has been maintained in G418 at 400 ug/ml with passage every four days into fresh medium. No loss of Aβ production of EGFP fluorescence has been seen over 23 passages.

Aβ EIA Analysis (Double Antibody Sandwich ELISA for hA β1-40/42):

Cell culture supernatants harvested 48 hr after transfection were analyzed in a standard Aβ EIA as follows. Human Aβ 1-40 or 1-42 was measured using monoclonal antibody (mAb) 6E10 (Senetek, St Louis. MO) and biotinylated rabbit antiserum 162 or 164 (New York State Institute for Basic Research, Staten Island, N.Y.) in a double antibody sandwich ELISA. The capture antibody 6E10 is specific to an epitope present on the N-terminal amino acid residues 1-16 of hAβ. The conjugated detecting antibodies 162 and 164 are specific for hAβ 1-40 and 1-42, respectively. Briefly, a Nunc Maxisorp 96 well immunoplate was coated with 100 μl/well of mAb 6E10 (5 μg/ml) diluted in 0.1 M carbonate-bicarbonate buffer, pH 9.6 and incubated at 4° C. overnight. After washing the plate 3× with 0.01M DPBS (Modified Dulbecco's Phosphate Buffered Saline (0.008M sodium phosphate, 0.002M potassium phosphate, 0.14M sodium chloride, 0.01 M potassium chloride, pH 7.4) from Pierce, Rockford, Ill.) containing 0.05% of Tween-20 (DPBST), the plate was blocked for 60 min with 200 μl of 10% normal sheep serum (Sigma) in 0.01M DPBS to avoid non-specific binding. Human Aβ 1-40 or 1-42 standards 100 μl/well (Bachem, Torrance, Calif.) diluted, from a 1 mg/ml stock solution in DMSO, in culture medium was added after washing the plate, as well as 100 μl/well of sample, e.g. conditioned medium of transfected cells. The plate was incubated for 2 hours at room temperature and 4° C. overnight. The next day, after washing the plate, 100 μl/well biotinylated rabbit antiserum 162 1:400 or 164 1:50 diluted in DPBST+0.5% BSA was added and incubated at room temperature for 1 hr 15 min. Following washes, 100 μl/well neutravidin-horseradish peroxidase (Pierce, Rockford, Ill.) diluted 1: 10,000 in DPBST was applied and incubated for 1 hr at room temperature. After the last washes 100 μl/well of o-phenylnediamine dihydrochloride (Sigma Chemicals, St. Louis, Mo.) in 50 mM citric acid/10 mM sodium phosphate buffer (Sigma Chemicals, St. Louis, Mo.), pH 5.0, was added as substrate and the color development was monitored at 450 nm in a kinetic microplate reader for 20 min. using Soft max Pro software. All standards and samples were run in triplicates. The samples with absorbance values falling within the standard curve were extrapolated from the standard curves using Soft max Pro software and expressed in pg/ml culture medium.

Results:

Addition of two lysine residues to the carboxyl terminus of APP695 greatly increases Aβ processing in HEK93 cells as shown by transient expression (Table 1). Addition of the di-lysine motif to APP695 increases Aβ processing to that seen with the APP695 containing the Swedish mutation. Combining the di-lysine motif with the Swedish mutation further increases processing by an additional 2.8 fold.

Cotransformation of HEK293 cells with pMG125.3 and pcDNA3.1 allowed dual selection of transformed cells for G418 resistance and high level expression of EGFP. After clonal selection by FACS, the cell line obtained, produces a remarkable 20,000 pg Aβ peptide per ml of culture medium after growth for 36 hr in 24 well plates. Production of Aβ peptide under various growth conditions is summarized in Table 2. TABLE 1 Release of Aβ peptide into the culture medium 48 hr after transient transfection of HEK293 cells with the indicated vectors containing wildtype or modified APP. Values tabulated are mean + SD and P-value for pairwise comparison using Student's t-test assuming unequal variances. Aβ 1-40 peptide APP Construct (pg/ml) Fold Increase P-value pIRES-EGFP vector  147 + 28 1.0 wt APP695 (142.3)  194 + 15 1.3 0.051 wt APP695-KK (124.1)  424 + 34 2.8 3 × 10−5 APP695-Sw (143.3)  457 + 65 3.1 2 × 10−3 APP695-SwKK (125.3) 1308 + 98 8.9 3 × 10−4

TABLE 2 Release of Aβ peptide from HEK125.3 cells under various growth conditions. Volume of Duration of Ab 1-40 Ab 1-42 Type of Culture Plate Medium Culture (pg/ml) (pg/ml) 24 well plate 400 ul 36 hr 28,036 1,439

Example 7 Antisense oligomer inhibition of Abeta processing in HEK125.3 cells

The sequences of Hu-Asp1 and Hu-Asp2 were provided to Sequitur, Inc (Natick, Mass.) for selection of targeted sequences and design of 2nd generation chimeric antisense oligomers using prorietary technology (Sequitur Ver. D Pat pending #3002). Antisense oligomers Lot# S644, S645, S646 and S647 were targeted against Asp1. Antisense oligomers Lot# S648, S649, S650 and S651 were targeted against Asp2. Control antisense oligomers Lot# S652, S653, S655, and S674 were targeted against an irrelevant gene and antisense oligomers Lot #S656, S657, S658, and S659 were targeted against a second irrelevant gene.

For transfection with the antisense oligomers, HEK125.3 cells were grown to about 50% confluence in 6 well plates in Minimal Essential Medium (MEM) supplemented with 10% fetal calf serum. A stock solution of oligofectin G (Sequitur Inc., Natick, Mass.) at 2 mg/ml was diluted to 50 μg/ml in serum free MEM. Separately, the antisense oligomer stock solution at 100 μM was diluted to 800 nM in Opti-MEM (GIBCO-BRL, Grand Island, N.Y.). The diluted stocks of oligofectin 0 and antisense oligomer were then mixed at a ratio of 1:1 and incubated at room temperature. After 15 min incubation, the reagent was diluted 10 fold into MEM containing 10% fetal calf serum and 2 ml was added to each well of the 6 well plate after first removing the old medium. After transfection, cells were grown in the continual presence of the oligofectin G/antisense oligomer. To monitor Ab peptide release, 400 μl of conditioned medium was removed periodically from the culture well and replaced with fresh medium beginning 24 hr after transfection. Data reported are from culture supernatants harvested 48 hr after transfection.

Results:

The 16 different antisense oligomers obtained from Sequitur Inc were transfected separately into HEK125.3 cells to determine their affect on AD peptide processing. Only antisense oligomers targeted against Asp1 & Asp2 reduced Abeta processing by HEK125.3 cells with those targeted against Asp2 having a greater inhibitory effect. Both Aβ (1-40) and Aβ (1-42) were inhibited by the same degree. In Table 3 percent inhibition is calculated with respect to untransfected cells. Antisense oligomer reagents giving greater than 50% inhibition are marked with an asterisk. Of the reagents tested, 3 of 4 antisense oligomers targeted against ASP1 gave an average 52% inhibition of Aβ 1-40 processing and 47% inhibition of Aβ 1-42 processing. For ASP2, 4 of 4 antisense oligomers gave greater than 50% inhibition with an average inhibition of 62% for Aβ 1-40 processing and 60% for Aβ 1-42 processing. TABLE 3 Inhibition of Aβ peptide release from HEK125.3 cells treated with antisense oligomers. Gene Antisense Abeta Abeta Targeted Oligomer (1-40) (1-42) Asp1-1 S644 62%* 56%* Asp1-2 S645 41%* 38%* Asp1-3 S646 52%* 46%* Asp1-4 S647  6% 25% Asp2-1 S648 71%* 67%* Asp2-2 S649 83%* 76%* Asp2-3 S650 46%* 50%* Asp2-4 S651 47%* 46%* Con1-1 S652 13% 18% Con1-2 S653 35% 30% Con1-3 S655  9% 18% Con1-4 S674 29% 18% Con2-1 S656 12% 18% Con2-2 S657 16% 19% Con2-3 S658  8% 35% Con2-4 S659  3% 18%

Example 8 Demonstration of Hu-Asp2 β-Secretase Activity in Cultured Cells

Several mutations in APP associated with early onset Alzheimer's disease have been shown to alter Aβ peptide processing. These flank the N- and C-terminal cleavage sites that release A□ from APP. These cleavage sites are referred to as the β-secretase and γ-secretase cleavage sites, respectively. Cleavage of APP at the β-secretase site creates a C-terminal fragment of APP containing 99 amino acids of 11,145 daltons molecular weight. The Swedish KM→NL mutation immediately upstream of the β-secretase cleavage site causes a general increase in production of both the 1-40 and 1-42 amino acid forms of A□ peptide. The London VF mutation (V717→F in the APP770 isoform) has little effect on total A□ peptide production, but appears to preferentially increase the percentage of the longer 1-42 amino acid form of A□ peptide by affecting the choice of γ-secretase cleavage site used during APP processing. Thus, we sought to determine if these mutations altered the amount and type of A□ peptide produced by cultured cells cotransfected with a construct directing expression of Hu-Asp2.

Two experiments were performed which demonstrate Hu-Asp2β-secretase activity in culture cells. In the first experiment, treatment of HEK1253 cells with antisense oligomers directed against Hu-Asp2 transcripts as described in Example 7 was found to decrease the amount of the C-terminal fragment of APP created by β-secretase cleavage (CTF99) (FIG. 9). This shows that Hu-Asp2 acts directly or indirectly to facilitate β-secretase cleavage. In the second experiment, increased expression of Hu-Asp2 in transfected mouse Neuro2A cells is shown to increase accumulation of the CTF99 β-secretase cleavage fragment (FIG. 10). This increase is seen most easily when a mutant APP-KK clone containing a C-terminal di-lysine motif is used for transfection. A further increase is seen when Hu-Asp2 is cotransfected with APP-Sw-KK containing the Swedish mutation KM→NL The Swedish mutation is known to increase cleavage of APP by the β-secretase.

A second set of experiments demonstrate Hu-Asp2 facilitates γ-secretase activity in cotransfection experiments with human embryonic kidney HEK293 cells. Cotransfection of Hu-Asp2 with an APP-KK clone greatly increases production and release of soluble Aβ 1-40 and Aβ1-42 peptides from HEK293 cells. There is a proportionately greater increase in the release of Aβ1-42. A further increase in production of Aβ1-42 is seen when Hu-Asp2 is cotransfected with APP-VF (SEQ ID No. 13 [nucleotide] and SEQ ID No. 14 [amino acid]) or APP-VF-KK SEQ ID No. 19 [nucleotide] and SEQ ID No. 20 [amino acid]) clones containing the London mutation V717→F. The V717→F mutation is known to alter cleavage specificity of the APP γ-secretase such that the preference for cleavage at the Aβ42 site is increased. Thus, Asp2 acts directly or indirectly to facilitate γ-secretase processing of APP at the β42 cleavage site.

Materials

Antibodies 6E10 and 4G8 were purchased from Senetek (St Louis, Mo.). Antibody 369 was obtained from the laboratory of Paul Greengard at the Rockefeller University. Antibody C8 was obtained from the laboratory of Dennis Selkoe at the Harvard Medical School and Brigham and Women's Hospital.

APP Constructs Used

The APP constructs used for transfection experiments comprised the following

-   -   APP wild-type APP695 (SEQ ID No. 9 and No. 10)     -   APP-Sw APP95 containing the Swedish KM→NL mutation (SEQ ID No.         11 and No. 12),     -   APP-VF APP695 containing the London V→F mutation (SEQ ID No. 13         and No. 14)     -   APP-KK APP695 containing a C-terminal KK motif (SEQ ID No. 15         and No. 16),     -   APP-Sw-KK APP695-Sw containing a C-terminal KK motif (SEQ ID No.         17 and No. 18),     -   APP-VF-KK APP695-VF containing a C-terminal KK motif (SEQ ID No.         19 and No. 20).         These were inserted into the vector pIRES-EGFP (Clontech, Palo         Alto Calif.) between the NotI and BstX1 sites using appropriate         linker sequences introduced by PCR.         Transfection of Antisense Oligomers or Plasmid DNA Constructs in         HEK293 Cells, HEK125.3 Cells and Neuro-2A Cells,

Human embryonic kidney HEK293 cells and mouse Neuro-2a cells were transfected with expression constructs using the Lipofectamine Plus reagent from Gibco/BRL Cells were seeded in 24 well tissue culture plates to a density of 70-80% confluence. Four wells per plate were-transfected with 2 μg DNA (3:1, APP:cotratsfectant), 8 μl Plus reagent, and 4 μl Lipofectamine in OptiMEM. OptiMEM was added to a total volume of 1 ml, distributed 200 μl per well and incubated 3 hours. Care was taken to hold constant the ratios of the two plasmids used for cotransfection is well as the total amount of DNA used in the transfection. The transfection media was replaced with DMEM, 10% FBS, NaPyruvate, with antibiotic/antimycotic and the cells were incubated under normal conditions (37°, 5% CO₂) for 48 hours. The conditioned media were removed to polypropylene tubes and stored at −80° C. until assayed for the content of Aβ1-40 and Aβ1-42 by EIA as described in the preceding examples. Transfection of antisense oligomers into HEK125.3 cells was as described in Example 7.

Preparation of Cell Extracts, Western Blot Protocol

Cells were harvested after being transfected with plasmid DNA for about 60 hours. First, cells were transferred to 15-ml conical tube from the plate and centrifuged at 1,500 rpm for 5 min to remove the medium. The cell pellets were washed with PBS for one time. We then lysed the cells with lysis buffer (10 mM HEPES, pH 7.9, 150 mM NaCl, 10% glycerol, 1 mM EGTA, 1 mM EDTA, 0.1 mM sodium vanadate and 1% NP-40). The lysed cell mixtures were centrifuged at 5000 rpm and the supernatant was stored at −20° C. as the cell extracts. Equal amounts of extracts from HEK125.3 cells transfected with the Asp2 antisense oligomers and controls were precipitated with antibody 369 that recognizes the C-terminus of APP and then CTF99 was detected in the immunoprecipitate with antibody 6E10. The experiment was repeated using C8, a second precipitating antibody that also recognizes the C-terminus of APP. For Western blot of extracts from mouse Neuro-2a cells cotransfected with Hu-Asp2 and APP-KK, APP-Sw-KK, APP-VF-KK or APP-VF, equal amounts of cell extracts were electrophoresed through 4-10% or 10-20% Tricine gradient gels (NOVEX, San Diego, Calif.). Full length APP and the CTF99 β-secretase product were detected with antibody 6E10.

Results

Transfection of HEK125.3 cells with Asp2-1 or Asp2-2 antisense oligomers reduces production of the CTF β-secretase product in comparison to cells similarly transfected with control oligomers having the reverse sequence (Asp2-1 reverse & Asp2-2 reverse) In cotransfection experiments, cotransfection of Hu-Asp2 into mouse Neuro-2a cells with the APP-KK construct increased the formation of CTF99. This was further increased if Hu-Asp2 was coexpresed with APP-Sw-KK, a mutant form of APP containing the Swedish KM→NL mutation that increases β-secretase processing.

Cotransfection of Hu-Asp2 with APP has little effect on Aβ40 production but increases Aβ42 production above background (Table 4). Addition of the di-lysine motif to the C-terminus of APP increases Aβ peptide processing about two fold, although Aβ40 and Aβ42 production remain quite low.(352 pg/ml and 21 pg/ml, respectively). Cotransfection of Asp2 with APP-KK further increases both Aβ40 and Aβ42 production. The stimulation of Aβ40 production by Hu-Asp2 is more than 3 fold, while production of Aβ42 increases by more than 10 fold. Thus, cotransfection of Hu-Asp2 and APP-KK constructs preferentially increases Aβ42 production.

The APP V717→F mutation has been shown to increase γ-secretase processing at the Aβ42 cleavage site. Cotransfection of Hu-Asp2 with the APP-VF or APP-VF-KK constructs increased Aβ42 production (a two fold increase with APP-VF and a four-fold increase with APP-VF-KK, Table 4), but had mixed effects on Aβ40 production (a slight decrease with APP-VF, and a two fold increase with APP-VF-KK in comparison to the pcDNA cotransfection control. Thus, the effect of Asp2 on Aβ42 production was proportionately greater leading to an increase in the ratio of Aβ42/total Aβ. Indeed, the ratio of Aβ42/total Aβ reaches a very high value of 42% in HEK293 cells cotransfected with Hu-Asp2 and APP-VF-KK Western blot showing reduction of CTF99 production by HEK125.3 cells transfected with antisense oligomers targeting the Hu-Asp2 mRNA. (right) Western blot showing increase in CTF99 production in mouse Neuro-2a cells cotransfected with Hu-Asp2 and APP-KK. A further increase in CTF99 production is seen in cells cotransfected with Hu-Asp2 and APP-Sw-KK. TABLE 4 Results of cotransfecting Hu-Asp2 or pcDNA plasmid DNA with various APP constructs containing the V717→F mutation that modifies γ-secretase processing. Cotransfection with Asp2 consistently increases the ratio of Aβ42/total Aβ. Values tabulated are Aβ peptide pg/ml. pcDNA Asp2 Cotransfection Cotransfection Aβ40 Aβ42 Aβ42/Total Aβ40 Aβ42 Aβ42/Total APP 192 ± 18 <4 <2%  188 ± 40  8 ± 10  3.9% APP-VF 118 ± 15 15 ± 19 11.5%  85 ± 7  24 ± 12 22.4% APP-KK 352 ± 24 21 ± 6  5.5% 1062 ± 101 226 ± 49 17.5% APP-VF-KK 230 ± 31 88 ± 24 27.7%  491 ± 35 355 ± 36   42%

EXAMPLE 9 Bacterial Expression of Human Asp2L

Expression of Recombinant Hu_Asp2L in E. coli

Hu-Asp2L can be expressed in E. coli after addition of N-terminal sequences such as a T7 tag (SEQ RD No. 21 and No. 22) or a 17 tag followed by a caspase 8 leader sequence (SEQ ID No. 23 and No. 24). Alternatively, reduction of the GC content of the 5′ sequence by site directed mutagenesis can be used to increase the yield of Hu-Asp2 (SEQ ID No. 25 and No. 26). In addition, Asp2 can be engineered with a proteolytic cleavage site (SEQ ID No. 27 and No. 28). To produce a soluble protein after expression and refolding, deletion of the transmembrane domain and cytoplasmic tail, or deletion of the membrane proximal region, transmembrane domain, and cytoplasmic tail is preferred.

Methods

PCR with primers containing appropriate linker sequences was used to assemble fusions of Asp2 coding sequence with N-terminal sequence modifications including a T7 tag (SEQ ID Nos. 21 and 22) or a T7-caspase 8 leader (SEQ ID Nos. 23 and 24). These constructs were cloned into the expression vector pet23a(+) [Novagen] in which a T7 promoter directs expression of a T7 tag preceding a sequence of multiple cloning sites. To clone Hu-Asp2 sequences behind the 17 leader of pET23a+, the following oligonucleotides were used for amplification of the selected Hu-Asp2 sequence: #553=GTGGATCCACCCAGCACGGCATCCGGCTG (SEQ ID No. 35), #554=GAAAGCTTTCATGACTCATCTGTCTGTGGAATGTTG (SEQ ID No. 36) which placed BamHI and HindIII sites flanking the 5′ and 3′ ends of the insert, respectively. The Asp2 sequence was amplified from the full length Asp2(b) cDNA cloned into pcDNA3.1 using the Advantage-GC cDNA PCR [Clontech] following the manufacturer's supplied protocol using annealing & extension at 68° C. in a two-step PCR cycle for 25 cycles. The insert and vector were cut with BamHI and HindIII, purified by electrophoresis through an agarose gel, then ligated using the Rapid DNA Ugation kit [Boerhinger Mannheim]. The ligation reaction was used to transform the E. coli strain JM109 (Promega) and colonies were picked for the purification of plasmid (Qiagen, Qiaprep minispin) and DNA sequence analysis. For inducible expression using induction with isopropyl b-D-thiogalactopyranoside (IPTG), the expression vector was transferred into E. coli strain BL21 (Statagene). Bacterial cultures were grown in LB broth in the presence of ampicillin at 100 ug/ml, and induced in log phase growth at an OD600 of 0.6-1.0 with 1 mM IPTG for 4 hour at 37° C. The cell pellet was harvested by centrifugation.

To clone Hu-Asp2 sequences behind the T7 tag and caspase leader (SEQ ID Nos. 23 and 24), the construct created above containing the T7-Hu-Asp2 sequence (SEQ ID Nos. 21 and 22) was opened at the BamHI site, and then the phosphorylated caspase 8 leader oligonucleotides #559=GATCGATGACTATCTCTGACTCTCCGCGTGAACAGGACG (SEQ ID No. 37), #560-GATCCGTCCTGTTCACGCGGAGAGTCAGAGATAGTCATC (SEQ ID No. 38) were annealed and ligated to the vector DNA. The 5′ overhang for each set of oligonucleotides was designed such that it allowed ligation into the BamHI site but not subsequent digestion with BamHI. The ligation reaction was transformed into JM109 as above for analysis of protein expression after transfer to E. coli strain BL21.

In order to reduce the GC content of the 5′ terminus of asp2, a pair of antiparallel oligos were designed to change degenerate codon bases in 15 amino acid positions from G/C to A/T (SEQ ID Nos. 25 and 26). The new nucleotide sequence at the 5′ end of asp2 did not change the encoded amino acid and was chosen to optimize E. Coli expression. The sequence of the sense linker is 5′ CGGCATCCGGCTGCCCCTGCGTAGCGGTCGGGTGGTGCTCCACTGGGTCTGCG TCTGCCCCGGGAGACCGACGAA G 3′ (SEQ ID No. 39). The sequence of the antisense linker is: 5′ CTTCGTCGGTCTTCCGGGGCAGACGCAGACCCAGTGGAGCACCACCCAGACCG CTACGCAGGGGCAGCCGGATGCCG 3′ (SEQ ID No. 40). After annealing the phosphorylated linkers together in 0.1 M NaCl-10 nM Tris, pH 7.4 they were ligated into unique Cla I and Sma I sites in Hu-Asp2 in the vector pTAC. For inducible expression using induction with isopropyl b-D-thiogalactopyranoside (IPTG), bacterial cultures were grown in LB broth in the presence of ampicillin at 100 ug/ml, and induced in log phase growth at an OD600 of 0.6-1.0 with 1 mM IPTG for 4 hour at 37° C. The cell pellet was harvested by centrifugation.

To create a vector in which the leader sequences can be removed by limited proteolysis with caspase 8 such that this liberates a Hu-Asp2 polypeptide beginning with the N-terminal sequence GSFV (SEQ ID Nos. 27 and 28), the following procedure was followed. Two phosphorylated oligonucleotides containing the caspase 8 cleavage site IETD, #571=5′ GATCGATGACTATCTCTGACTCTCCGCTGGACTCTGGTATCGAAACCGACG (SEQ ID No. 41) and #572=GATCCGTCGGTTTCGATACCAGAGTCCAGCGGAGAGTCAGAGATAGTCATC (SEQ ID No. 42) were annealed and ligated into pET23a+ that had been opened with BamHI. After transformation into JM109, the purified vector DNA was recovered and orientation of the insert was confirmed by DNA sequence analysis. +, the following oligonucleotides were used for amplification of the selected Hu-Asp2 sequence: #573=5′AAGGATCCTTTGTGGAGATGGTGGACAACCTG, (SEQ ID No. 43) #554=GAAAGCTTTCATGACTCATCTGTCTGTGGAATGTTG(SEQ ID No. 44) which placed BamHI and HindIII sites flanking the 5′ and 3′ ends of the insert, respectively. The Asp2 sequence was amplified from the full length Asp2 cDNA cloned into pcDNA3.1 using the Advantages cDNA PCR [Clontech] following the manufacturer's supplied protocol using annealing & extension at 68° C. in a two-step PCR cycle for 25 cycles. The insert and vector were cut with BamHI and HindIII purified by electrophoresis through an agarose gel, then ligated using the Rapid DNA Ugation kit [Boerhinger Mannheim]. The ligation reaction was used to transform the E. coli strain JM109 [Promega] and colonies were picked for the purification of plasmid (Qiagen, Qiaprep minispin) and DNA sequence analysis. For inducible expression using induction with isopropyl b-D thiogalactopyranoside (IPTG), the expression vector was transferred into E. coli strain BL21 (Statagene). Bacterial cultures were grown in LB broth in the presence of ampicillin at 100 ug/ml, and induced in log phase growth at an OD600 of 0.6-1.0 with 1 mM IPTG for 4 hour at 37° C. The cell pellet was harvested by centrifugation.

To assist purification, a 6-His tag can be introduced into any of the above constructs following the T7 leader by opening the construct at the BamHI site and then ligating in the annealed, phosphorylated oligonucleotides containing the six histidine sequence #565-GATCGCATCATCACCATCACCATG (SEQ ID No. 45), #566=GATCCATGGTGATGGTGATGATGC (SEQ ID No. 46). The 5′ overhang for each set of oligonucleotides was designed such that it allowed ligation into the BamHI site but not subsequent digestion with BamHI.

Preparation of Bacterial Pellet:

36.34 g of bacterial pellet representing 10.8 L of growth was dispersed into a total volume of 200 ml using a 20 nm tissue homogenizer probe at 3000 to 5000 rpm in 2M KCl, 0.1M Tris, 0.05M EDTA, 1 mM DTT. The conductivity adjusted to about 193 mMhos with water.

After the pellet was dispersed, an additional amount of the KCl solution was added, bringing the total volume to 500 ml. This suspension was homogenized further for about 3 minutes at 5000 rpm using the same probe. The mixture was then passed through a Rannie high-pressure homogenizer at 10,000 psi.

In all cases, the pellet material was carried forward, while the soluble fraction was discarded. The resultant solution was centrifuged in a GSA rotor for 1 hr. at 12,500 rpm. The pellet was resuspended in the same solution (without the DTT) using the same tissue homogenizer probe at 2,000 rpm. After homogenizing for 5 minutes at 3000 rpm, the volume was adjusted to 500 ml with the same solution, and spun for 1 hr. at 12,500 rpm. The pellet was then resuspended as before but this tine the final volume was adjusted to 1.5 L with the same solution prior to homogenizing for 5 minutes. After centrifuging at the same speed for 30 minutes, this procedure was repeated. The pellet was then resuspended into about 150 ml of cold water, pooling the pellets from the six centrifuge tubes used in the GSA rotor. The pellet has homogenized for 5 minutes at 3,000 rpm, volume adjusted to 250 ml with cold water, then spun for 30 minutes. Weight of the resultant pellet was 17.75 g.

Summary: Lysis of bacterial pellet in KCl solution, followed by centrifugation in a GSA rotor was used to initially prepare the pellet. The same solution was then used an additional three times for resuspension/homogenization. A final water wash/homogenization was then performed to remove excess KCl and EDTA.

Solublization of rHuAsp2L:

A ratio of 9-10 ml/gram of pellet was utilized for solubilizing the rHuAsp2L from the pellet previously described. 17.75 g of pellet was thawed, and 150 ml of 8M guanidine HCl, 5 mM βME, 0.1% DEA, was added. 3M Tris was used to titrate the pH to 8.6. The pellet was initially resuspended into the guanidine solution using a 20 mm tissue homogenizer probe at 1000 rpm. The mixture was then stirred at 4° C. for 1 hour prior to centrifugation at 12,500 rpm for 1 hour in GSA rotor. The resultant supernatant was then centrifuged for 30 min at 40.000×g in an SS-34 rotor. The final supernatant was then stored at −20° C., except for 50 ml.

Immobilized Nickel Affinity Chromatography of Solubilized rHuAsp2L:

The following solutions were utilized:

-   -   A) 6M Guanidine HCl, 0.1M NaP, pH 8.0, 0.01M Tris, 5 mM βME, 0.5         mM Imidazole     -   A′) 6M Urea, 20 mM NaP, pH 6.80, 50 mM NaCl     -   B′) 6M Urea, 20 mM NaP, pH 6.20, 50 mM NaCl, 12 mM Imidazole     -   C′) 6M Urea, 20 mM NaP, pH 6.80,50 mM NaCl, 300 mM Imidazole         Note: Buffers A′ and C′ were mixed at the appropriate ratios to         give intermediate concentrations of Imidazole.

The 50 ml of solubilized material was combined with 50 ml of buffer A prior to adding to 100-125 ml Qiagen Ni-NTA SuperFlow (pre-equilibrated with buffer A) in a 5×10 cm Bio-Rad econo column. This was shaken gently overnight at 4° C. in the cold room.

Chromatography Steps:

-   -   1) Drained the resultant flow through.     -   2) Washed with 50 ml buffer A (collecting into flow through         fraction)     -   3) Washed with 250 ml buffer A (wash 1)     -   4) Washed with 250 ml buffer A (wash 2)     -   5) Washed with 250 ml buffer A′     -   6) Washed with 250 ml buffer B′     -   7) Washed with 250 ml buffer A′     -   8) Eluted with 250 ml 75 mM Imidazole     -   9) Eluted with 250 ml 150 mM Imidazole (150-1)     -   10) Eluted with 250 ml 150 mM Imidazole (150-2)     -   11) Eluted with 250 ml 300 mM Imidazole (300-1)     -   12) Eluted with 250 ml 300 mM Imidazole (300-2)     -   13) Eluted with 250 ml 300 mM Imidazole (300-3)         Chromatography Results:

The rHuAsp eluted at 75 mM Imidazole through 300 mM Imidazole. The 75 mM fraction, as well as the first 150 mM Imidazole (150-1) fraction contained contaminating proteins as visualized on Coomassie Blue stained gels. Therefore, fractions 150-2 and 300-1 will be utilized for refolding experiments since they contained the greatest amount of protein (see Coomassie Blue stained gel).

Refolding Experiments of rHuAsp2L:

Experiment 1:

Forty ml of 150-2 was spiked with 1M DTT, 3M Tris, pH 7.4 and DEA to a final concentration of 6 m, 50 mM, and 0.1% respectively. This was diluted suddenly (while stirring) with 200 ml of (4° C.) cold 20 mM NaP, pH 6.8, 150 mM NaCl. This dilution gave a final Urea concentration of 1 M. This solution remained clear, even if allowed to set open to the air at RT or at 4° C.

After setting open to the air for 4-5 hours at 4° C., this solution was then dialyzed overnight against 20 mM NaP, pH 7.4, 150 mM NaCl, 20% glycerol. This method effectively removes the urea in the solution without precipitation of the protein.

Experiment 2:

Some of the 150-2 eluate was concentrated 2×on an Amicon Centriprep, 10,000 MWCO then treated as in Experiment 1. This material also stayed in solution, with no visible precipitation.

Experiment 3

89 ml of the 150-2 eluate was spiked with 1M DTT, 3M Tris, pH 7.4 and DEA to a final concentration of 6 mM, 50 mM, and 0.1% respectively. This was diluted suddenly (while stirring) with 445 ml of (4° C.) cold 20 mM NaP, pH 6.8, 150 mM NaCl. This solution appeared clear, with no apparent precipitation. The solution was removed to RT and stirred for 10 minutes prior to adding MEA to a final concentration of 0.1 mM. This was stirred slowly at RT for 1 hr. Cystamine and CUSO₄ were then added to final concentrations of 1 mM and 10 μM respectively. The solution was stirred slowly at RT for 10 minutes prior to being moved to the 4° C. cold room and shaken slowly overnight, open to the air.

The following day, the solution (still clear, with no apparent precipitation) was centrifuged at 100,000×g for 1 hour. Supernatants from multiple runs were pooled, and the bulk of the stabilized protein was dialyzed against 20 mM NaP, pH 7.4, 150 mM NaCl, 20% glycerol. After dialysis, the material was stored at −20° C.

Some (about 10 ml) of the protein solution (still in 1M Urea) was saved back for biochemical analyses, and frozen at −20° C. for storage.

Example 10 Expression of Hu-Asp2 and Derivatives In Insect Cells

Expression by baculovirus infection—The coding sequence of Hu-Asp2 and several derivatives were engineered for expression in insect cells using the PCR. For the full-length sequence, a 5′-sense oligonucleotide primer that modified the translation initiation site to fit the Kozak consensus sequence was paired with a 3′-antisense primer that contains the natural translation termination codon in the Hu-Asp2 sequence. PCR amplification of the pcDNA3.1(hygro)1Hu-Asp2 template (see Example 12). Two derivatives of Hu-Asp2 that delete the C-terminal transmembrane domain (SEQ ID No. 29 and No.30) or delete the transmembrane domain and introduce a hexa-histidine tag at the C-terminus (SEQ ID No. 31 and No. 32) were also engineered using the PCR. The same 5′-sense oligonucleotide primer described above was paired with either a 3′-antisense primer that (1) introduced a translation termination codon after codon 453 (SEQ ID No. 3) or (2) incorporated a hexa-histidine tag followed by a translation termination codon in the PCR using pcDNA3.1(hygro)1Hu_Asp-2L as the template. In all cases, the PCR reactions were performed amplified for 15 cycles using PwoI DNA polymerase (Boehringer-Mannheim) as outlined by the supplier. The reaction products were digested to completion with BamHI and NotI and ligated to BamHI and NotI digested baculovirus transfer vector pVL1393 (Invitrogen). A portion of the ligations was used to transform competent E coli DH5α cells followed by antibiotic selection on LB-Amp. Plasmid DNA was prepared by standard alkaline lysis and banding in CsCl to yield the baculovirus transfer vectors pVL1393/Asp2, pVL1393/Asp2ΔTM and pVL1393/Asp2ΔTM(His)₆. Creation of recombinant baculoviruses and infection of sf9 insect cells was performed using standard methods.

Expression by transfection—Transient and stable expression of Hu-Asp2ΔTM and Hu-Asp2ΔTM(His)₆ in High 5 insect cells was performed using the insect expression vector pIZ/V5-His. The DNA inserts from the expression plasmids vectors pVL1393/Asp2, pVL1393/Asp2ΔTM and pVL1393/Asp2ATM(His)₆ were excised by double digestion with BamHI and NotI and subcloned into BamHI and NotI digested pIZ/V5-His using standard methods. The resulting expression plasmids, referred to as pIZ/Hu-Asp2ΔTM and pIZ/Hu-Asp2ATM(His)₆, were prepared as described above.

For transfection, High 5 insect cells were cultured in High Five serum free medium supplemented with 10; μg/ml gentamycin at 27° C. in sealed flasks. Transfections were performed using High five cells, High five serum flee media supplemented with 10 μg/ml gentamycin, and InsectinPlus liposomes (Invitrogen, Carlsbad, Calif.) using standard methods.

For large scale transient transfections 1.2×10⁷ high five cells were plated in a 150 mm tissue culture dish and allowed to attach at room temperature for 15-30 minutes. During the attachment time the DNA/liposome mixture was prepared by mixing 6 ml of serum free media, 60 pg Asp2ATM/pIZ (+/−His) DNA and 120 μl of Insectin Plus and incubating at room temperature for 15 minutes. The plating media was removed from the dish of cells and replaced with the: DNA/liposome mixture for 4 hours at room temperature with constant rocking at 2 rpm. An additional 6 ml of media was added to the dish prior to incubation for 4 days at 27° C. in a humid incubator. Four days post transfection the media was harvested, clarified by centrifugation at 500×g, assayed for Asp2 expression by Western blotting. For stable expression, the cells were treated with 50 μg/ml Zeocin and the surviving pool used to prepared clonal cells by limiting dilution followed by analysis of the expression level as noted above.

Purification of Hu-Asp2ΔTM and Hu-Asp2ΔTM(His)₆—Removal of the transmembrane segment from Hu-Asp2 resulted in the secretion of the polypeptide into the culture medium. Following protein production by either baculovirus infection or transfection, the conditioned medium was harvested, clarified by centrifugation, and dialyzed against Tris-HCl (pH 8.0). This material was then purified by sucessive chromatography by anion exchange (Tris-HCl, pH 8.0) followed by cation exchange chromatography (Acetate buffer at pH 4.5) using NaCl gradients. The elution profile was monitored by (1) Western blot analysis and (2) by activity assay using the peptide substrate described in Example 12. For the Hu-Asp2ΔTM(His)₆, the conditioned medium was dialyzed against Tris buffer (pH 8.0) and purified by sequential chromatography on IMAC resin followed by anion exchange chromatography.

Sequence analysis of the purified Hu-Asp2ΔTM(His)₆ protein revealed that the signal peptide had been cleaved [TQHGIRLPLR].

Example 11 Expression of Hu-Asp2 In CHO cells

Heterologous expression of Hu_Asp-2L in CHO-K1 cells—The entire coding sequence of Hu-Asp2 was cloned into the mammalian expression vector pcDNA3.1(+)Hygro (Invitrogen, Carlsbad, Calif.) which contains the CMV immediate early promotor and bGH polyadenylation signal to drive over expression. The expression plasmid, pcDNA3.1(+)Hygro/Hu-Asp2, was prepared by alkaline lysis and banding in CsCl and completely sequenced on both strands to verify the integrity of the coding sequence.

Wild-type Chinese hamster ovary cells (CHO-K1) were obtained from the ATCC. The cells were maintained in monolayer cultures in α-MEM containing 10% FCS at 37° C. in 5% CO₂. Two 100 mm dishes of CHO-K1 cells (60% confluent) were transfected with pcDNA3.1(+)/Hygro alone (mock) or pcDNA3.1(+)Hygro/u-Asp2 using the cationic liposome DOTAP as recommended by the supplier. The cells were treated with the plasmid DNA/liposome mixtures for 15 hr and then the medium replaced with growth medium containing 500 Units/ml hygromycin B. In the case of pcDNA3.1(+)Hygro/Hu-Asp2 transfected CHO-K1 cells, individual hygromycin B-resistant cells were cloned by limiting dilution. Following clonal expansion of the individual cell lines, expression of Hu-Asp2 protein was accessed by Western blot analysis using a polyclonal rabbit antiserum raised against recombinant Hu-Asp2 prepared by expression in E coli. Near confluent dishes of each cell line were harvested by scraping into PBS and the cells recovered by centrifugation. The cell pellets were resuspended in cold lysis buffer (25 MM Tris-HCl (8.0)15 mM EDTA) containing protease-inhibitors and the cells lysed by sonication. The soluble and membrane fractions were separated by centrifugation (105,000×g, 60 min) and normalized amounts of protein from each fraction were then separated by SDS-PAGE. Following electrotransfer of the separated polypeptides to PVDF membranes, Hu_Asp-2L protein was detected using rabbit anti-Hu-Asp2 antiserum (1/1000 dilution) and the antibody-antigen complexes were visualized using alkaline phosphatase conjugated goat anti-rabbit antibodies (1/2500). A specific immunoreactive protein with an apparent Mr value of 65 kDa was detected in pcDNA3.1 (+)Hygro/Hu-Asp2 transfected cells and not mock-transfected cells. Also, the Hu-Asp2 polypeptide was only detected in the membrane fraction, consistent with the presence of a signal peptide and single transmembrane domain in the predicted sequence. Based on this analysis, clone #5 had the highest expression level of Hu-Asp2 protein and this production cell lines was scaled up to provide material for purification.

Purification of recombinant Hu_Asp-2L from CHO-K1/Hu-Asp2 clone #5 a typical purification, clone #5 cell pellets derived from 20 150 mm dishes of confluent cells, were used as the starting material. The cell pellets were resuspended in 50 ml cold lysis buffer as described above. The cells were lysed by polytron homogenization (2×20 sec) and the lysate centrifuged at 338,000×g for 20 minutes. The membrane pellet was then resuspended in 20 ml of cold lysis buffer containing 50 mM β-octylglucoside followed by rocking at 4° C. for 1 hr. The detergent extract was clarified by centrifugation at 338,000×g for 20 minutes and the supernatant taken for further analysis.

The β-octylglucoside extract was applied to a Mono Q anion exchange column that was previously equilibrated with 25 mM Tris-HCl (pH 8.0)/50 mM β-octylglucoside. Following sample application, the column was eluted with a linear gradient of increasing NaCl concentration (0-1.0 M over 30 minutes) and individual fractions assayed by Western blot analysis and for β-secretase activity (see below). Fractions-containing both Hu_Asp-2L immunoreactivity and β-secretase activity were pooled and dialyzed against 25 mM NaOAc (pH 4.5)50 mM β-octylglucoside. Following dialysis, precipitated material was removed by centrifugation and the soluble material chromatographed on a MonoS cation exchange column that was previously equilibrated in 25 mM NaOAc (pH 4.5)/50 mM β-octylglucoside. The column was eluted using a linear gradient of increasing NaCl concentration (0-1.0 M over 30 minutes) and individual fractions assayed by Western blot analysis and for β-secretase activity. Fractions containing both Hu-Asp2 immunoreactivity and β-secretase activity were combined and determined to be >90% pure by SDS-PAGE/Coomassie Blue staining.

Example 12 Assay of Hu-Asp2 β-Secretase Activity Using Peptide Substrates

β-secretase assay—β-secretase activity was measured by quantifying the hydrolysis of a synthetic peptide containing the APP Swedish mutation by RP-HPLC with UV detection. Each reaction contained 50 mM Na-MES (pH 5.5), 1% β-octylglucoside, peptide substrate (SEVNLDAEFR, 70 μM) and enzyme (1-5 μg protein). Reactions were incubated at 37° C. for various times and the reaction products were resolved by RP-HPLC using a linear gradient from 0-70 B over 30 minutes (A=0.1% TFA in water, B=)0.1% TFA/10% water/90% AcCN). The elution profile was monitored by absorbance at 214 nm. In preliminary experiments, the two product peaks which eluted before the intact peptide substrate, were confirmed to have the sequence DAEFR and SEVNL using both Edman sequencing and MADLI-TOF mass spectrometry. Percent hydrolysis of the peptide substrate was calculated by comparing the integrated peak areas for the two product peptides and the starting material derived from the absorbance at 214 nm. The specificity of the protease cleavage reaction was determined by performing the β-secretase assay in the presence of a cocktail of protease inhibitors (8 μM pepstatin A, 10 μM leupeptin, 10 μM E64, and 5 mM EDTA).

An alternative β-secretase assay utilizes internally quenched fluorescent substrates to monitor enzyme activity using fluorescence spectroscopy in a single sample or multiwell format. Each reaction contained 50 mM Na-MES (pH 5.5), peptide substrate MCA-EVKMDAEF[K-DNP] (BioSource International) (50 μM) and purified Hu-Asp-2 enzyme. These components were equilibrated to 37° C. for various times and the reaction initiated by addition of substrate. Excitation was performed at 330 nm and the reaction kinetics were monitored by measuring the fluorescence emission at 390 nm. To detect compounds that modulate Hu-Asp-2 activity the test compounds were added during the preincubation phase of the reaction and the kinetics of the reaction monitored as described above. Activators are scored as compounds that increase the rate of appearance of fluorescence while inhibitors decrease the rate of appearance of fluorescence.

It will be clear that the invention may be practiced otherwise than as particularly described in the foregoing description and examples.

Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, are within the scope of the invention.

The entire disclosure of all publications cited herein are hereby incorporated by reference. 

1-150. (canceled)
 151. A purified polypeptide comprising a mammalian Asp2 polypeptide that cleaves a mammalian β-amyloid precursor protein (APP), or a fragment, analog, or derivative of said mammalian Asp2 polypeptide that retains the APP cleaving activity.
 152. A purified polypeptide according to claim 151, selected from the group consisting of: (a) a polypeptide comprising a purified human Asp2(a) amino acid sequence set forth in SEQ ID NO: 4 or a fragment thereof that cleaves APP; (b) a polypeptide comprising a purified human Asp2(b) amino acid sequence set forth in SEQ ID NO: 6 or a fragment thereof that cleaves APP; (c) a polypeptide comprising the murine Asp2 amino acid sequence set forth in SEQ ID NO: 8, or a fragment thereof that cleaves APP; (d) a polypeptide comprising a purified polypeptide having an amino acid sequence that is at least 95% identical to (a), (b), or (c).
 153. A purified polypeptide according to claim 151, said polypeptide comprising a portion of the human Asp2(a) amino acid sequence set forth in SEQ ID NO: 4, said portion including amino acids 22-501 of SEQ ID NO: 4 and lacking amino acids 1-21.
 154. A polypeptide according to claim 153, beginning with the N-terminal sequence ETDEEP.
 155. A purified polypeptide according to claim 151, said polypeptide comprising a portion of the human Asp2(a) amino acid sequence set forth in SEQ ID NO: 4 effective to cleave APP, said polypeptide lacking transmembrane domain amino acid residues 455-477 of SEQ ID NO:
 4. 156. A polypeptide according to claim 154, said polypeptide lacking amino acids 454-501 of SEQ ID NO:
 4. 157. A purified polypeptide according to claim 151, said polypeptide comprising a portion of the human Asp2(b) amino acid sequence set forth in SEQ ID NO: 6, said portion including amino acids 22-476 of SEQ ID NO: 6 and lacking amino acids 1-21.
 158. A purified polypeptide according to claim 151, said polypeptide comprising a portion of the human Asp2(b) amino acid sequence set forth in SEQ ID NO: 6 effective to cleave APP, said polypeptide lacking transmembrane domain amino acid residues 430-452 of SEQ ID NO:
 6. 159. A purified polypeptide according to claim 151 comprising a fragment of a mammalian Asp2 polypeptide, Wherein the purified polypeptide lacks the transmembrane domain of said mammalian Asp2 polypeptide.
 160. A fusion protein comprising a polypeptide of claim 151, and which further includes a heterologous tag amino acid sequence.
 161. A polypeptide of claim 151, wherein the polypeptide cleaves human APP or human APP-Sw at the β-secretase recognition site.
 162. A polypeptide of claim 151, wherein the polypeptide lacks any mammalian Asp2 pro-peptide sequence.
 163. A polypeptide according to claim 151, selected from the group consisting of: (a) a polypeptide comprising a portion of the amino acid sequence set forth in SEQ ID NO: 4 effective to cleave APP, wherein the polypeptide lacks amino acids 1-45 of SEQ ID NO: 4; and (b) a polypeptide comprising a portion of the amino acid sequence set forth in SEQ ID NO: 6 effective to cleave APP, wherein the polypeptide lacks amino acids 1-45 of SEQ ID NO:
 6. 164. A purified polynucleotide comprising a nucleotide sequence that encodes a polypeptide of claim
 151. 165. A polynucleotide according to claim 164, selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence set forth in SEQ ID NO: 3; (b) a polynucleotide comprising the nucleotide sequence set forth in SEQ ID NO: 5; (c) a polynucleotide comprising the nucleotide sequence set forth in SEQ ID NO: 7; (d) a polynucleotide comprising a nucleotide sequence that is at least 95% identical to (a), (b), or (c), and that encodes a polypeptide that cleaves APP; and (e) a fragment of (a), (b), (c), or (d) that encodes a polypeptide that cleaves APP.
 166. A polynucleotide according to claim 164 comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS: 21, 23, 25, 27, 29, and
 31. 167. A purified polynucleotide according to claim 164, selected from the group consisting of: (a) a purified polynucleotide that comprises a nucleotide sequence that encodes amino acids 22-501 of SEQ ID NO: 4 and lacks adjacent nucleotide sequence encoding amino acids 1-21 of SEQ ID NO: 4; and (b) a purified polynucleotide that comprises a nucleotide sequence that encodes amino acids 22-476 of SEQ ID NO: 6 and lacks adjacent nucleotide sequence encoding amino acids 1-21 of SEQ ID NO:
 6. 168. A purified polynucleotide according to claim 164, selected from the group consisting of: (a) a purified polynucleotide comprising a nucleotide sequence that encodes a portion of the human Asp2(a) amino acid sequence set forth in SEQ ID NO: 4 effective to cleave APP, and wherein the polynucleotide lacks adjacent nucleotide sequence encoding transmembrane domain amino acid residues 455-477 of SEQ ID NO: 4; and (b) a purified polynucleotide comprising a nucleotide sequence that encodes a portion of the human Asp2(a) amino acid sequence set forth in SEQ ID NO: 6 effective to cleave APP, and wherein the polynucleotide lacks adjacent nucleotide sequence encoding transmembrane domain amino acid residues 430-452 of SEQ ID NO:
 6. 169. A purified polynucleotide according to claim 168, said polynucleotide lacking nucleotide sequence encoding amino acids 454-501 of SEQ ID NO:
 4. 170. A purified polynucleotide according to claim 164, comprising a fragment of a mammalian Asp2 polynucleotide, wherein the fragment lacks nucleotide sequence encoding the transmembrane domain of said mammalian Asp2 polypeptide.
 171. A purified polynucleotide according to claim 164, wherein the polynucleotide lacks a nucleotide sequence encoding a mammalian Asp2 pro-peptide sequence.
 172. A vector comprising a polynucleotide according to claim
 164. 173. A vector according to claim 172 that is an expression vector wherein the polynucleotide is operably linked to an expression control sequence.
 174. A host cell transformed or transfected with a polynucleotide according to claim
 164. 175. A host cell transformed or transfected with a vector according to claim
 173. 176. A host cell according to claim 175 that is a mammalian cell.
 177. A host cell according to claim 175 that expresses the polypeptide on its surface.
 178. A host cell according to claim 175 that secretes the polypeptide encoded by the polynucleotide, wherein the secreted polypeptide lacks a transmembrane domain.
 179. A host cell according to claim 174; wherein the host cell is transfected with a nucleic acid comprising a nucleotide sequence that encodes an amyloid precursor protein (APP) or fragment thereof that includes a protease recognition site recognized by the polypeptide.
 180. A host cell according to claim 179, wherein the host cell is transfected with a nucleic acid comprising a nucleotide sequence that encodes an amyloid precursor protein (APP).
 181. A host cell according to claim 180, wherein the host cell is transfected with a nucleic acid comprising a nucleotide sequence that encodes an amyloid precursor protein (APP) that includes two carboxy-terminal lysine residues.
 182. A host cell according to claim 179, wherein the APP or fragment thereof includes the APP Swedish mutation sequence KM→NL immediately upstream of the β-secretase cleavage site.
 183. A host cell according to claim 179, that expresses the polypeptide and the APP or APP fragment on its surface.
 184. A method of making a polypeptide that cleaves APP, comprising steps of culturing a host cell according to claim 174 in a culture medium under conditions in which the cell produces the polypeptide that is encoded by the polynucleotide.
 185. A method according to claim 184, further comprising a step of purifying the polypeptide from the cell or the: culture medium.
 186. A method for identifying agents that inhibit the activity of human Asp2 aspartyl protease (Hu-Asp2), comprising the steps of: (a) contacting amyloid precursor protein (APP) and a polypeptide according to claim 151 in the presence and absence of a test agent; (b) determining the APP processing activity of the polypeptide in the presence and absence of the test agent; and (c) comparing the APP processing activity of the polypeptide in the presence of the test agent to the activity in the absence of the test agent to identify an agent that inhibits the APP processing activity of the polypeptide, wherein reduced activity in the presence of the test agent identifies an agent that inhibits Hu-Asp2 activity.
 187. A method according to claim 186, wherein the polypeptide is a recombinant polypeptide purified and isolated from a cell transformed or transfected with a polynucleotide comprising a nucleotide sequence that encodes the polypeptide.
 188. A method according to claim 186, wherein the polypeptide is expressed in a cell transformed or transfected with a polynucleotide comprising a nucleotide sequence that encodes the polypeptide, wherein the contacting comprises growing the cell in the presence and absence of the test agent, and wherein the determining step comprises measuring APP processing activity of the cell.
 189. A method according to claim 186, wherein the determining step comprises measuring the production of amyloid beta peptide by the cell in the presence and absence of the test agent.
 190. A method according to claim 188, wherein the cell is a human embryonic kidney cell line 293 (HEK293) cell.
 191. A method according to claim 187 wherein the nucleotide sequence is selected from the group consisting of: (a) a nucleotide sequence encoding the Hu-Asp2(a) amino acid sequence set forth in SEQ ID NO: 4; (b) a nucleotide sequence encoding the Hu-Asp2(b) amino acid sequence set forth in SEQ ID NO: 6; (c) a nucleotide sequence encoding a fragment of Hu-Asp2(a) (SEQ ID NO: 4) or Hu-Asp2(b) (SEQ ID NO: 6), wherein said fragment exhibits aspartyl protease activity characteristic of Hu-Asp2(a) or Hu-Asp2(b); and (d) a nucleotide sequence of a polynucleotide that hybridizes under stringent hybridization conditions to a Hu-Asp2-encoding polynucleotide selected from the group consisting of SEQ ID NO: 3 and SEQ ID NO:
 5. 192. A method according claim 187, wherein the Hu-Asp2 comprises the Hu-Asp2(a) amino acid sequence set forth in SEQ ID NO:
 4. 193. A method according to claim 187, wherein the Hu-Asp2 comprises the Hu-Asp2(b) amino acid sequence set forth in SEQ ID NO:
 6. 194. A method according to claim 187, wherein the Hu-Asp2 comprises a fragment of Hu-Asp2(a) (SEQ ID NO: 4) or Hu-Asp2(b) (SEQ ID NO: 6), wherein said fragment exhibits aspartyl protease activity characteristic of Hu-Asp2(a) or Hu-Asp2(b).
 195. A method according to claim 187, wherein the cell comprises a vector that comprises the polynucleotide.
 196. A method according to claim 186, wherein the APP comprises the Swedish mutation (K→N, M→L) adjacent to the β-secretase processing site.
 197. A method according to claim 186, wherein the APP further comprises a carboxy-terminal di-lysine.
 198. A method for identifying agents that modulate the activity of Asp2 aspartyl protease, comprising the steps of: (a) contacting a purified and isolated polypeptide according to claim 151 and amyloid precursor protein (APP) in the presence and absence of a test agent, wherein the Asp2′ aspartyl protease is encoded by a nucleic acid molecule that hybridizes under stringent hybridization conditions to a Hu-Asp2-encoding polynucleotide selected from the group consisting of SEQ ID NO: 4 and SEQ ID NO: 6; (b) determining the APP processing activity of the polypeptide in the presence and absence of the test agent; and (c) comparing the APP processing activity of the polypeptide in the presence of the test agent to the activity in the absence of the agent to identify agents that modulate the activity of the polypeptide, wherein a modulator that is an Asp2 inhibitor reduces APP processing and a modulator that is an Asp2 agonist increases such processing.
 199. A method according to claim 186, further comprising a step of treating Alzheimer's Disease with an agent identified as an inhibitor of Hu-Asp2 according to steps (a)-(c).
 200. A method according to claim 186, further comprising a step of manufacturing a medicament for the treatment of Alzheimer's Disease with an inhibitor identified according to steps (a)-(c).
 201. A method for assaying for modulators of β-secretase activity, comprising the steps of: (a) contacting a first composition with a second composition both in the presence and in the absence of a putative modulator compound, wherein the first composition comprises a polypeptide according to claim 151, and wherein the second composition comprises a substrate polypeptide having an amino acid sequence comprising a β-secretase cleavage site; (b) measuring cleavage of the substrate polypeptide in the presence and in the absence of the putative modulator compound; and (c) identifying modulators of β-secretase activity from a difference in cleavage in the presence versus in the absence of the putative modulator compound, wherein a modulator that is a β-secretase antagonist reduces such cleavage and a modulator that is a β-secretase agonist increases such cleavage.
 202. A method according to claim 201, wherein the polypeptide of the first composition comprises a polypeptide purified and isolated from a cell transformed or transfected with a polynucleotide comprising a nucleotide sequence that encodes the polypeptide.
 203. A method according to claim 201, wherein the polypeptide of the first composition is expressed in a cell transformed or transfected with a polynucleotide comprising a nucleotide sequence that encodes the polypeptide, and wherein the measuring step comprises measuring APP processing activity of the cell.
 204. A method according to claim 201, wherein the first composition comprises a purified human Asp2 polypeptide.
 205. A method according to claim 201, wherein the first composition comprises a soluble fragment of a human Asp2 polypeptide that retains Asp2 β-secretase activity.
 206. A method according to claim 205, wherein the soluble fragment is a fragment lacking an Asp2 transmembrane domain.
 207. A method according to claim 205, wherein the substrate polypeptide of the second composition comprises the amino acid sequence SEVNLDAEFR.
 208. A method according to claim 205, wherein the substrate polypeptide of the second composition comprises the amino acid sequence EVKMDAEF.
 209. A method according to claim 205, wherein the second composition comprises a polypeptide having an amino acid sequence of a human amyloid precursor protein (APP).
 210. A method according to claim 204, wherein the human amyloid precursor protein is selected from the group consisting of: APP695, APP751, and APP770.
 211. A method according to claim 210, wherein the human amyloid precursor protein includes at least on mutation selected from a KM→NL Swiss mutation and a V→F London mutation.
 212. A method according to claim 209, wherein the polypeptide having an amino acid sequence of a human APP further comprises an amino acid sequence comprising a marker sequence attached amino-terminal to the amino acid sequence of the human amyloid precursor protein.
 213. A method according to claim 209, wherein the polypeptide having an amino acid sequence of a human APP further comprises two lysine residues attached to the carboxyl terminus of the amino acid sequence of the human APP.
 214. A method according to claim 201, wherein the second composition comprises a eukaryotic cell that expresses amyloid precursor protein (APP) or a fragment thereof containing a β-secretase cleavage site.
 215. A method according to claim 214, wherein the APP expressed by the host cell is an APP variant that includes two carboxyl-terminal lysine residues.
 216. A method according to claim 201, further comprising a step of treating Alzheimer's Disease with an agent identified as an inhibitor of Hu-Asp2 according to steps (a)-(c).
 217. A method according to claim 201, further comprising a step of manufacturing a medicament for the treatment of Alzheimer's Disease with a modulator identified as an antagonist according to steps (a)-(c).
 218. A method of reducing cellular production of amyloid beta (AP) from amyloid precursor protein (APP), comprising step of transforming or transfecting cells with an anti-sense reagent capable of reducing Asp2 polypeptide production by reducing Asp2 transcription or translation in the cells, wherein reduced Asp2 polypeptide production in the cells correlates with reduced cellular processing of APP into Aβ.
 219. A method of reducing cellular production of amyloid beta (Aβ) from amyloid precursor protein (APP), comprising steps of: (a) identifying mammalian cells that produce Aβ; and (b) transforming or transfecting the cells with an anti-sense reagent capable of reducing Asp2 polypeptide production by reducing Asp2 transcription or translation in the cells, wherein reduced Asp2 polypeptide production in the cells correlates with reduced cellular processing of APP into Aβ.
 220. A method according to claim 219, wherein the identifying step comprises diagnosing Alzheimer's disease, where Alzheimer's disease correlates with the existence of cells that produce Aβ that forms amyloid plaques in the brain.
 221. A method according to claim 218, wherein the cell is a neural cell.
 222. A method according to claim 218, wherein the anti-sense reagent comprises an oligonucleotide comprising a single stranded nucleic acid sequence capable of binding to a Hu-Asp mRNA.
 223. A method according to claim 218, wherein the anti-sense reagent comprises an oligonucleotide comprising a single stranded nucleic acid sequence capable of binding to a Hu-Asp DNA.
 224. An isolated nucleic acid molecule comprising a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of: (a) a nucleotide sequence encoding a Hu-Asp polypeptide selected from the group consisting of Hu-Asp1, Hu-Asp2(a), and Hu-Asp2(b), wherein said Hu-Asp1, Hu-Asp2(a) and Hu-Asp2(b) polypeptides have the complete amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, and SEQ ID No:6, respectively; and (b) a nucleotide sequence complementary to the nucleotide sequence of (a).
 225. An isolated nucleic acid molecule comprising polynucleotide which hybridizes under stringent conditions to a polynucleotide comprising a nucleotide sequence selected from: (a) a nucleotide sequence encoding a Hu-Asp polypeptide selected from the group consisting of Hu-Asp1, Hu-Asp2(a), and Hu-Asp2(b), wherein said Hu-Asp1, Hu-Asp2(a) and Hu-Asp2(b) polypeptides have the complete amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, and SEQ ID No:6, respectively; and (b) a nucleotide sequence complementary to the nucleotide sequence of (a).
 226. A vector comprising the nucleic acid molecule of claim
 224. 227. The vector of claim 226, wherein said nucleic acid molecule is operably linked to a promoter for the expression of a Hu-Asp polypeptide.
 228. A host cell comprising the vector of claim
 227. 229. A method of obtaining a Hu-Asp polypeptide comprising culturing the host cell of claim 228 and isolating said Hu-Asp polypeptide.
 230. An isolated Hu-Asp1 polypeptide comprising an amino acid sequence at least 95% identical to a sequence comprising the amino acid sequence of SEQ ID NO:2.
 231. An isolated antibody that binds specifically to the Hu-Asp polypeptide of claim
 230. 232. A method according to Claim 184, in which the determining or measuring step comprises measuring the amount of amyloid beta-peptide released into growth medium of the cell and/or the amount of CTF99 fragments of APP in cell lysates.
 233. The method of claim 232 wherein the cell is from a human, rodent or insect cell line.
 234. A method for identifying agents that modulate the activity of human Asp1 aspartyl protease (Hu-Asp1), comprising the steps of: (a) contacting amyloid precursor protein (APP) and a Hu-Asp1 polypeptide in the presence and absence of the test agent; (b) determining the APP processing activity of the polypeptide in the presence and absence of the test agent; and (c) comparing the APP processing activity of the polypeptide in the presence of the test agent to the activity in the absence of the test agent to identify an agent that modulates the APP processing activity of the polypeptide, wherein a modulator that is an Asp1 inhibitor reduces such cleavage and a modulator that is a Asp1 agonist increases such cleavage.
 235. A method according to claim 234 wherein the polypeptide comprises an amino acid sequence at least 95% identical to a sequence comprising the amino acid sequence of SEQ ID NO:
 2. 236. A method according to claim 234, wherein the polypeptide is a recombinant polypeptide purified and isolated from a cell transformed or transfected with a polynucleotide comprising a nucleotide sequence that encodes the polypeptide.
 237. A method according to claim 234, wherein the polypeptide is expressed in a cell transformed or transfected with a polynucleotide comprising a nucleotide sequence that encodes the polypeptide, wherein the contacting comprises growing the cell in the presence and absence of the test agent, and wherein the determining step comprises measuring APP processing activity of the cell.
 238. A method according to claim 237, wherein the determining step comprises measuring the production of amyloid beta peptide by the cell in the presence and absence of the test agent.
 239. A method according to claim 237, wherein the cell is a human embryonic kidney cell line 293 (HEK293) cell.
 240. A method according to claim 236 wherein the nucleotide sequence is selected from the group consisting of (a) a nucleotide sequence encoding the Hu-Asp1 amino acid sequence set forth in SEQ ID NO: 1; (b) a nucleotide sequence encoding a fragment of Hu-Asp1 (SEQ ID NO: 1), wherein said fragment exhibits aspartyl protease activity characteristic of Hu-Asp1 (c) a nucleotide sequence of a polynucleotide that hybridizes under stringent hybridization conditions to a Hu-Asp1-encoding polynucleotide having the sequence set forth in SEQ ID NO:
 1. 241. A method according to claim 237, wherein the cell comprises a vector that comprises the polynucleotide.
 242. A method according to claim 234, wherein the APP comprises the Swedish mutation (K→N, M→L) adjacent to the β-secretase processing site.
 243. A method according to claim 234, wherein the APP further comprises a carboxy-terminal di-lysine.
 244. A method according to claim 234, wherein the test agent is an inhibitor.
 245. A method according to claim 234, wherein the test agent is an agonist.
 246. A method according to claim 234, further comprising a step of treating Alzheimer's Disease with an agent identified as an modulator of Hu-Asp1 according to steps (a)-(c).
 247. A method according to claim 234, further comprising a step of making a medicament for the treatment of Alzheimer's Disease with a test agent identified as an inhibitor according to steps (a)-(c).
 248. A method of reducing cellular production of amyloid beta (AP) from amyloid precursor protein (APP), comprising step of transforming or transfecting cells with an anti-sense reagent capable of reducing Asp1 polypeptide production by reducing Asp1 transcription or translation in the cells, wherein reduced Asp1 polypeptide production in the cells correlates with reduced cellular processing of APP into Aβ.
 249. A method of reducing cellular production of amyloid beta (AP) from amyloid precursor protein (APP), comprising steps of: (a) identifying mammalian cells that produce Aβ; and (b) transforming or transfecting the cells with an anti-sense reagent capable of reducing Asp1 polypeptide-production by reducing Asp1 transcription or translation in the cells, wherein reduced Asp 1 polypeptide production in the cells correlates with reduced cellular processing of APP into Aβ.
 250. A method according to claim 249, wherein the identifying step comprises diagnosing Alzheimer's disease, where Alzheimer's disease correlates with the existence of cells that produce Aβ that forms amyloid plaques in the brain.
 251. A method according to any one of claims 249, wherein the anti-sense, reagent comprises an oligonucleotide comprising a single stranded nucleic acid sequence capable of binding to a Hu-Asp1 mRNA.
 252. A method for the identification of an agent that decreases the activity of a Hu-Asp polypeptide selected from the group consisting of Hu-Asp1, Hu-Asp1(a), and Hu-Asp2(b), the method comprising (a) determining the activity of said Hu-Asp polypeptide in the presence of a test agent and in the absence of a test agent; and (b) comparing the activity of said Hu-Asp polypeptide determined in the presence of said test agent to the activity of said Hu-Asp polypeptide determined in the absence of said test agent; whereby a lower level of activity in the presence of said test agent than in the absence of said test agent indicates that said test agent has decreased the activity of said Hu-Asp polypeptide. 